pioglitazone has been researched along with Innate Inflammatory Response in 178 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pioglitazone was associated with increased peripheral insulin sensitivity (+23%-72%, standardized mean difference of 0." | 9.41 | Can pioglitazone be used for optimization of nutrition in critical illness? A systematic review. ( Davies, TW; Fowler, AJ; McClelland, TJ; Pearse, R; Prowle, J; Puthucheary, Z, 2023) |
| "To investigate the clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease (CHD)." | 9.20 | [Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease]. ( Borzykh, OA; Byelan, OV; Kaidashev, IP; Mamontova, TV, 2015) |
| " This study investigates the impact of a pioglitazone plus metformin therapy on biomarkers of inflammation and platelet activation in comparison to a treatment with glimepiride plus metformin." | 9.15 | The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. ( Forst, T; Fuchs, W; Hohberg, C; Lehmann, U; Löbig, M; Müller, J; Musholt, PB; Pfützner, A; Schöndorf, T, 2011) |
| "This study investigated the effects of pioglitazone (PIO), ramipril (RAM), or their combination (PIRA) on low-grade inflammation in nondiabetic hypertensive patients with increased cardiovascular risk." | 9.15 | Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study. ( Dekordi, LA; Forst, T; Fuchs, W; Hanefeld, M; Kleine, I; Müller, J; Pfützner, A, 2011) |
| "The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging." | 9.15 | Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011) |
| "This study examined whether pioglitazone, an agonist of peroxisome proliferator-activated receptor gamma, may stabilize vulnerable plaque with use of ultrasound evaluation of carotid artery plaque echolucency in patients with acute coronary syndrome (ACS) and type 2 diabetes mellitus (DM)." | 9.14 | Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome. ( Fujioka, D; Hirano, M; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Nakamura, K; Nakamura, T; Obata, JE; Saito, Y; Sano, K; Yano, T, 2009) |
| "To compare the effect of addition of pioglitazone and acarbose to sulphonylureas and metformin therapy on metabolic parameters and on markers of endothelial dysfunction and vascular inflammation in type 2 diabetic patients." | 9.14 | Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Randazzo, S; Salvadeo, SA, 2010) |
| "Our aim was to investigate if the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone modulates inflammation through PPARalpha mechanisms." | 9.13 | The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. ( Devchand, PR; Hamdy, O; Horton, ES; Nehra, V; Orasanu, G; Plutzky, J; Ziouzenkova, O, 2008) |
| "Luteolin, a flavonoid compound with anti-inflammatory activity, has been reported to alleviate cerebral ischemia/reperfusion (I/R) injury." | 8.12 | Luteolin alleviates inflammation and autophagy of hippocampus induced by cerebral ischemia/reperfusion by activating PPAR gamma in rats. ( Fan, R; Guo, L; Li, D; Li, L; Liang, H; Ma, L; Pan, G; Qiu, J, 2022) |
| " In the present study, it was examined whether treatment with PPAR‑γ agonist pioglitazone (PIO) is beneficial in counteracting SEV‑induced neuroinflammation and cognitive decline in a rat model of CIH." | 7.91 | Pioglitazone prevents sevoflurane‑induced neuroinflammation and cognitive decline in a rat model of chronic intermittent hypoxia by upregulating hippocampal PPAR‑γ. ( Dong, P; Fei, J; Li, D; Li, L; Li, N; Lin, Q; Lu, L; Yang, B; Zhang, X, 2019) |
| "The study showed pioglitazone might exert an inhibitory effect on hepatic inflammation and fibrosis in NAFLD." | 7.85 | Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study. ( Deng, W; Meng, Z; Sun, A; Yang, Z, 2017) |
| "We aimed to study the antitumor effects of the PPARγ agonist pioglitazone on human retinoblastoma." | 7.85 | Pioglitazone inhibits growth of human retinoblastoma cells via regulation of NF-κB inflammation signals. ( Bi, Z; Liu, Y; Wang, F, 2017) |
| "The findings suggest that LPS challenge exacerbates IR in db/db mice by altering the expression of genes in WAT involved in adipogenesis and inflammation, which is effectively controlled by pioglitazone treatment." | 7.85 | Effect of pioglitazone on metabolic features in endotoxemia model in obese diabetic db/db mice. ( Chatterjee, A; Jain, MR; Malik, U; Mohapatra, J; Nagar, J; Ramachandran, B; Sharma, M, 2017) |
| "Our study suggests that pioglitazone can reduce the number of plaque thrombosis incidences by decreasing plaque inflammation." | 7.81 | Plaque Thrombosis is Reduced by Attenuating Plaque Inflammation with Pioglitazone and is Evaluated by Fluorodeoxyglucose Positron Emission Tomography. ( Lv, SZ; Wang, ZM; Yan, YF; Zhang, MD; Zhang, YH; Zhao, QM; Zhao, XC, 2015) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 7.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "It is concluded that oral administration of the pioglitazone attenuates morphine-induced tolerance and the neuroinflammation in the lumbar region of the rat spinal cord." | 7.81 | Protective effect of pioglitazone on morphine-induced neuroinflammation in the rat lumbar spinal cord. ( Charkhpour, M; Ghanbarzadeh, S; Ghavimi, H; Hassanzadeh, K; Khorrami, A; Mesgari, M; Yousefi, B, 2015) |
| "The insulin sensitizing thiazolidinedione drugs, rosiglitazone and pioglitazone are specific peroxisome proliferator-activated receptor-gamma agonists and reduce pro-inflammatory responses in patients with type 2 diabetes and coronary artery disease, and may be beneficial in sepsis." | 7.80 | Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis. ( Chima, R; Kaplan, J; Nowell, M; Zingarelli, B, 2014) |
| "Pioglitazone treatment decreases portosystemic shunting via modulation of splanchnic inflammation and neoangiogenesis." | 7.80 | Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. ( Angermayr, B; Boucher, Y; Fuhrmann, V; Grahovac, J; Horvatits, T; Klein, S; Mitterhauser, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Stift, J; Trauner, M; Trebicka, J, 2014) |
| " Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients." | 7.78 | The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ( Isogawa, A; Iwamoto, M; Koike, K; Ohki, T; Ohsugi, M; Omata, M; Tagawa, K; Toda, N; Yoshida, H, 2012) |
| "The purpose of this study was to test the hypothesis that atrial fibrosis and enhanced vulnerability to AF evoked by pressure overload can be attenuated by pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, via suppression of inflammatory profibrotic signals." | 7.77 | Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. ( Hara, M; Kume, O; Nagano-Torigoe, Y; Nakagawa, M; Saikawa, T; Takahashi, N; Teshima, Y; Wakisaka, O; Yoshimatsu, H; Yufu, K, 2011) |
| "We used the F344 rat model of aging, and monitored behavioral, electrophysiological, and molecular variables to assess the effects of pioglitazone (PIO-Actos(R) a TZD) on several peripheral (blood and liver) and central (hippocampal) biomarkers of aging." | 7.76 | Effects of long-term pioglitazone treatment on peripheral and central markers of aging. ( Anderson, KL; Avdiushko, MG; Blalock, EM; Chen, KC; Cohen, DA; Gant, JC; Pancani, T; Phelps, JT; Popovic, J; Porter, NM; Searcy, JL; Thibault, O, 2010) |
| "The aim of this paper was to investigate the inhibitory effect of peroxisome proliferator-activated receptor-gamma (PPARγ) agonist pioglitazone on microglia inflammation induced by lipopolysaccharide (LPS)." | 7.76 | PPARγ agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways. ( Aiguo, S; Ji, H; Li, X; Wang, H; Xiang, L; Zhang, F, 2010) |
| "To determine whether peroxisome proliferator-activated receptor (PPAR) gamma ligands improve survival of patients with septic shock we treated a mouse model of sepsis [apolipoprotein (Apo) E) knockout mice] with pioglitazone, a PPAR-gamma ligand." | 7.74 | Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis. ( Haraguchi, G; Imai, T; Isobe, M; Kosuge, H; Maejima, Y; Suzuki, J; Yoshida, M, 2008) |
| " We investigated the effect of pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on dextran sulfate sodium-induced colonic mucosal injury and inflammation in mice." | 7.71 | Pioglitazone, a PPAR-gamma ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-kappaB-cytokine cascade. ( Handa, O; Ichikawa, H; Naito, Y; Takagi, T; Tomatsuri, N; Yoshida, N; Yoshikawa, T, 2002) |
| "Fenofibrate was shown to increase serum sirtuin 1 and decrease serum fetuin A levels in obese patients." | 6.80 | Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis. ( Abd El-Razek, RS; El-Hefnawy, MH; El-Mesallamy, HO; Noureldein, MH, 2015) |
| "Chronic low-grade inflammation is a common feature of insulin resistant states, including obesity and type 2 diabetes." | 6.78 | Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. ( Aroda, V; Ciaraldi, TP; Henry, RR; Mudaliar, SR, 2013) |
| "Pioglitazone has demonstrated a favorable CV profile relative to other oral antidiabetic drugs (OADs) in outcome and observational studies." | 6.75 | Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. ( Arora, V; Jacks, R; Perez, A; Spanheimer, R, 2010) |
| "Pioglitazone also mitigated most of the steatohepatitis-related changes, however, memantine was more effective in most of the studied parameters." | 5.91 | A novel approach to repositioning memantine for metabolic syndrome-induced steatohepatitis: Modulation of hepatic autophagy, inflammation, and fibrosis. ( Abdel-Ghanyª, RH; Alsemehᵇ, AE; Elgharbawyª, AS; Metwallyª, SS; Zakariaª, EM, 2023) |
| " These beneficial effects of VIT D may expand its use by diabetics combined with antidiabetic drugs due to its anti-inflammatory, antioxidant, and antiapoptotic properties." | 5.72 | Vitamin D Combined with Pioglitazone Mitigates Type-2 Diabetes-induced Hepatic Injury Through Targeting Inflammation, Apoptosis, and Oxidative Stress. ( Elyamany, MF; Hamouda, HA; Mansour, SM, 2022) |
| "Major disease phenotypes include: adrenomyeloneuropathy (AMN), progressive spinal cord axonal degeneration, and cerebral ALD (C-ALD), inflammatory white matter demyelination and degeneration." | 5.72 | Therapeutic potential of deuterium-stabilized (R)-pioglitazone-PXL065-for X-linked adrenoleukodystrophy. ( DeWitt, S; Hallakou-Bozec, S; Jacques, V; Kaur, N; Klett, E; Moller, DE; Monternier, PA; Nagaraja, TN; Parasar, P; Singh, J; Theurey, P, 2022) |
| "Pioglitazone treatment was associated with increased expression of chemokine (Cxcl1, Cxcl2, and Ccl20) and cytokine genes (Tnfa, Il6, and Cfs3) in bronchial brushes obtained 6 h after infection." | 5.72 | The PPAR-γ agonist pioglitazone exerts proinflammatory effects in bronchial epithelial cells during acute Pseudomonas aeruginosa pneumonia. ( de Vos, AF; Ferreira, BL; Otto, NA; Ramirez-Moral, I; Salomão, R; van der Poll, T, 2022) |
| "Treatment with pioglitazone, BCP, BCP + CB2R antagonist, AM630, or BCP + PPAR-γ antagonist, BADGE was started from the 9th week and continued till the 12th week." | 5.51 | Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: Involvement of CB2 and PPAR-γ receptors. ( El-Fayoumi, HM; Mahmoud, MF; Youssef, DA, 2019) |
| "Treatment with pioglitazone, significantly attenuated the postnatal propionic acid-induced social impairment, repetitive behavior, hyperactivity, anxiety and low exploratory activity." | 5.51 | A selective peroxisome proliferator-activated receptor-γ agonist benefited propionic acid induced autism-like behavioral phenotypes in rats by attenuation of neuroinflammation and oxidative stress. ( Mirza, R; Sharma, B, 2019) |
| "Atherosclerosis was induced via a high-cholesterol diet and endothelial denudation." | 5.48 | Effect of pioglitazone on inflammation and calcification in atherosclerotic rabbits : An ( Feng, T; Li, J; Nie, M; Xu, J; Xu, Z; Yan, Y; Zhang, M; Zhao, Q; Zhao, X, 2018) |
| "Treatment with pioglitazone reduced the density of CLS in periprostatic fat and suppressed levels of TNFα, TGFβ, and the chemokine monocyte chemoattractant protein-1 (MCP-1)." | 5.48 | Pioglitazone Inhibits Periprostatic White Adipose Tissue Inflammation in Obese Mice. ( Bhardwaj, P; Dannenberg, AJ; Falcone, DJ; Giri, DD; Miyazawa, M; Subbaramaiah, K; Wang, H; Zhou, XK, 2018) |
| "Inflammation is a known risk factor in diabetes." | 5.43 | Pioglitazone alleviates inflammation in diabetic mice fed a high-fat diet via inhibiting advanced glycation end-product-induced classical macrophage activation. ( Ge, J; Jin, X; Liu, L; Shen, C; Yao, T; Zhou, Z, 2016) |
| " Pioglitazone was associated with increased peripheral insulin sensitivity (+23%-72%, standardized mean difference of 0." | 5.41 | Can pioglitazone be used for optimization of nutrition in critical illness? A systematic review. ( Davies, TW; Fowler, AJ; McClelland, TJ; Pearse, R; Prowle, J; Puthucheary, Z, 2023) |
| "Pioglitazone treatment increased the cross-sectional area of adipocytes by 18% (p = 0." | 5.40 | Pioglitazone treatment reduces adipose tissue inflammation through reduction of mast cell and macrophage number and by improving vascularity. ( Adu, A; Finlin, BS; Kern, PA; Peterson, CA; Rasouli, N; Shipp, LR; Spencer, M; Yang, L; Zhu, B, 2014) |
| "Pioglitazone-treated monkeys also showed a dose-dependent modulation of CD68-ir inflammatory cells, that was significantly decreased for 5 mg/kg treated animals compared to placebo (P = 0." | 5.37 | The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. ( Bondarenko, V; Brunner, K; Emborg, ME; Joers, V; Johnson, JA; Kemnitz, JW; Simmons, HA; Swanson, CR; Ziegler, TE, 2011) |
| "Inflammation is an essential component of vulnerable or high-risk atheromas." | 5.37 | Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. ( Calcagno, C; Dickson, SD; Fayad, ZA; Fisher, EA; Fuster, V; Hayashi, K; Lin, J; Moon, MJ; Moshier, E; Mounessa, JS; Nicolay, K; Roytman, M; Rudd, JH; Tsimikas, S; Vucic, E, 2011) |
| " We analyzed peripheral biomarkers, including leukocyte PGC-1α and target gene expression, plasma interleukin 6 (IL-6) as a marker of inflammation, and urine 8-hydroxydeoxyguanosine (8OHdG) as a marker of oxidative DNA damage." | 5.20 | Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects. ( Baker, L; Clark-Matott, J; Dunlop, SR; Elm, J; Emborg, M; Graebner, AK; Kamp, C; Morgan, JC; Ravina, B; Ross, GW; Sharma, S; Simon, DK; Simuni, T, 2015) |
| "To investigate the clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease (CHD)." | 5.20 | [Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease]. ( Borzykh, OA; Byelan, OV; Kaidashev, IP; Mamontova, TV, 2015) |
| " This study investigates the impact of a pioglitazone plus metformin therapy on biomarkers of inflammation and platelet activation in comparison to a treatment with glimepiride plus metformin." | 5.15 | The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. ( Forst, T; Fuchs, W; Hohberg, C; Lehmann, U; Löbig, M; Müller, J; Musholt, PB; Pfützner, A; Schöndorf, T, 2011) |
| "This study investigated the effects of pioglitazone (PIO), ramipril (RAM), or their combination (PIRA) on low-grade inflammation in nondiabetic hypertensive patients with increased cardiovascular risk." | 5.15 | Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study. ( Dekordi, LA; Forst, T; Fuchs, W; Hanefeld, M; Kleine, I; Müller, J; Pfützner, A, 2011) |
| "The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging." | 5.15 | Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011) |
| "This study examined whether pioglitazone, an agonist of peroxisome proliferator-activated receptor gamma, may stabilize vulnerable plaque with use of ultrasound evaluation of carotid artery plaque echolucency in patients with acute coronary syndrome (ACS) and type 2 diabetes mellitus (DM)." | 5.14 | Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome. ( Fujioka, D; Hirano, M; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Nakamura, K; Nakamura, T; Obata, JE; Saito, Y; Sano, K; Yano, T, 2009) |
| "The aim of the study was to compare the effects of the addition of sitagliptin or metformin to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients on body weight, glycemic control, beta-cell function, insulin resistance, and inflammatory state parameters." | 5.14 | Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA, 2010) |
| "The aim of the study was to compare the effects of vildagliptin added to pioglitazone or glimepiride on metabolic and insulin resistance related-indices in poorly controlled type 2 diabetic patients (T2DM)." | 5.14 | Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. ( Ciccarelli, L; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Mereu, R; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA, 2010) |
| "To compare the effect of addition of pioglitazone and acarbose to sulphonylureas and metformin therapy on metabolic parameters and on markers of endothelial dysfunction and vascular inflammation in type 2 diabetic patients." | 5.14 | Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Randazzo, S; Salvadeo, SA, 2010) |
| "Our aim was to investigate if the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone modulates inflammation through PPARalpha mechanisms." | 5.13 | The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. ( Devchand, PR; Hamdy, O; Horton, ES; Nehra, V; Orasanu, G; Plutzky, J; Ziouzenkova, O, 2008) |
| "Pioglitazone has diverse multiple effects on metabolic and inflammatory processes that have the potential to influence cardiovascular disease pathophysiology at various points in the disease process, including atherogenesis, plaque inflammation, plaque rupture, haemostatic disturbances and microangiopathy." | 4.86 | Pioglitazone and mechanisms of CV protection. ( Erdmann, E; Wilcox, R, 2010) |
| "Luteolin, a flavonoid compound with anti-inflammatory activity, has been reported to alleviate cerebral ischemia/reperfusion (I/R) injury." | 4.12 | Luteolin alleviates inflammation and autophagy of hippocampus induced by cerebral ischemia/reperfusion by activating PPAR gamma in rats. ( Fan, R; Guo, L; Li, D; Li, L; Liang, H; Ma, L; Pan, G; Qiu, J, 2022) |
| "5 % cholic acid and 60 % cocoa butter for 6 weeks causing a number of metabolic and hepatic alterations including insulin resistance, dyslipidemia, systemic inflammation, increased hepatic oxidative stress and lipid peroxidation, hepatic steatosis, lobular inflammation, as well as increased markers of liver inflammation and hepatocyte apoptosis." | 4.12 | Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms. ( Aly, RG; Alzaim, I; El-Mallah, A; El-Yazbi, AF; Shaaban, HH; Wahid, A, 2022) |
| " However, liraglutide induced weight loss, improved glycaemic control, reduced ALT and AST and showed some beneficial effects upon steatosis and lobular inflammation." | 3.91 | Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue. ( Brockbank, S; Bruun, MF; Cruwys, S; Daniels, SJ; Detlefsen, S; Hein, P; Henriksen, K; Hjuler, ST; Karsdal, MA; Leeming, DJ, 2019) |
| " In the present study, it was examined whether treatment with PPAR‑γ agonist pioglitazone (PIO) is beneficial in counteracting SEV‑induced neuroinflammation and cognitive decline in a rat model of CIH." | 3.91 | Pioglitazone prevents sevoflurane‑induced neuroinflammation and cognitive decline in a rat model of chronic intermittent hypoxia by upregulating hippocampal PPAR‑γ. ( Dong, P; Fei, J; Li, D; Li, L; Li, N; Lin, Q; Lu, L; Yang, B; Zhang, X, 2019) |
| "The study showed pioglitazone might exert an inhibitory effect on hepatic inflammation and fibrosis in NAFLD." | 3.85 | Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study. ( Deng, W; Meng, Z; Sun, A; Yang, Z, 2017) |
| "We aimed to study the antitumor effects of the PPARγ agonist pioglitazone on human retinoblastoma." | 3.85 | Pioglitazone inhibits growth of human retinoblastoma cells via regulation of NF-κB inflammation signals. ( Bi, Z; Liu, Y; Wang, F, 2017) |
| "The findings suggest that LPS challenge exacerbates IR in db/db mice by altering the expression of genes in WAT involved in adipogenesis and inflammation, which is effectively controlled by pioglitazone treatment." | 3.85 | Effect of pioglitazone on metabolic features in endotoxemia model in obese diabetic db/db mice. ( Chatterjee, A; Jain, MR; Malik, U; Mohapatra, J; Nagar, J; Ramachandran, B; Sharma, M, 2017) |
| " The aim of the present study was to elucidate the role of the TLR4‑dependent signaling pathway, and examine the effect of pioglitazone on hepatic fibrosis, through modulation of the TLR4 pathway in a mouse model of nutritional fibrotic steatohepatitis." | 3.83 | TLR4‑dependent signaling pathway modulation: A novel mechanism by which pioglitazone protects against nutritional fibrotic steatohepatitis in mice. ( Du, J; Kong, L; Nan, Y; Niu, X; Wang, R; Zhang, Y; Zhao, S, 2016) |
| "Our study suggests that pioglitazone can reduce the number of plaque thrombosis incidences by decreasing plaque inflammation." | 3.81 | Plaque Thrombosis is Reduced by Attenuating Plaque Inflammation with Pioglitazone and is Evaluated by Fluorodeoxyglucose Positron Emission Tomography. ( Lv, SZ; Wang, ZM; Yan, YF; Zhang, MD; Zhang, YH; Zhao, QM; Zhao, XC, 2015) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 3.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "It is concluded that oral administration of the pioglitazone attenuates morphine-induced tolerance and the neuroinflammation in the lumbar region of the rat spinal cord." | 3.81 | Protective effect of pioglitazone on morphine-induced neuroinflammation in the rat lumbar spinal cord. ( Charkhpour, M; Ghanbarzadeh, S; Ghavimi, H; Hassanzadeh, K; Khorrami, A; Mesgari, M; Yousefi, B, 2015) |
| "PPARγ agonist pioglitazone pretreatment significantly reduces infarct volume and attenuates neurological deficits following spinal cord ischemia." | 3.80 | A peroxisome proliferator-activated receptor gamma agonist attenuates neurological deficits following spinal cord ischemia in rats. ( Han, S; Hwang, J; Kim, H; Lim, C; Min, S; Nahm, SF; Park, K; Park, S, 2014) |
| "The insulin sensitizing thiazolidinedione drugs, rosiglitazone and pioglitazone are specific peroxisome proliferator-activated receptor-gamma agonists and reduce pro-inflammatory responses in patients with type 2 diabetes and coronary artery disease, and may be beneficial in sepsis." | 3.80 | Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis. ( Chima, R; Kaplan, J; Nowell, M; Zingarelli, B, 2014) |
| "Pioglitazone treatment decreases portosystemic shunting via modulation of splanchnic inflammation and neoangiogenesis." | 3.80 | Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. ( Angermayr, B; Boucher, Y; Fuhrmann, V; Grahovac, J; Horvatits, T; Klein, S; Mitterhauser, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Stift, J; Trauner, M; Trebicka, J, 2014) |
| "Telmisartan acts beneficially against diabetes-induced inflammation and improves insulin resistance in pre-diabetes OLETF rats fed with HFD." | 3.79 | Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action. ( Li, LY; Luo, R; Sun, LT; Tian, FS; Xiong, HL; Zhao, ZQ; Zheng, XL, 2013) |
| " Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients." | 3.78 | The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ( Isogawa, A; Iwamoto, M; Koike, K; Ohki, T; Ohsugi, M; Omata, M; Tagawa, K; Toda, N; Yoshida, H, 2012) |
| "The purpose of this study was to test the hypothesis that atrial fibrosis and enhanced vulnerability to AF evoked by pressure overload can be attenuated by pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, via suppression of inflammatory profibrotic signals." | 3.77 | Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. ( Hara, M; Kume, O; Nagano-Torigoe, Y; Nakagawa, M; Saikawa, T; Takahashi, N; Teshima, Y; Wakisaka, O; Yoshimatsu, H; Yufu, K, 2011) |
| "Candesartan protected against vascular inflammation and restored endothelial function after SES implantation." | 3.77 | Candesartan with pioglitazone protects against endothelial dysfunction and inflammatory responses in porcine coronary arteries implanted with sirolimus-eluting stents. ( Daida, H; Dohi, T; Iesaki, T; Kasai, T; Kubota, N; Miyauchi, K; Ogita, M; Tsuboi, S; Tsuruta, R; Yokoyama, T, 2011) |
| "We used the F344 rat model of aging, and monitored behavioral, electrophysiological, and molecular variables to assess the effects of pioglitazone (PIO-Actos(R) a TZD) on several peripheral (blood and liver) and central (hippocampal) biomarkers of aging." | 3.76 | Effects of long-term pioglitazone treatment on peripheral and central markers of aging. ( Anderson, KL; Avdiushko, MG; Blalock, EM; Chen, KC; Cohen, DA; Gant, JC; Pancani, T; Phelps, JT; Popovic, J; Porter, NM; Searcy, JL; Thibault, O, 2010) |
| "The aim of this paper was to investigate the inhibitory effect of peroxisome proliferator-activated receptor-gamma (PPARγ) agonist pioglitazone on microglia inflammation induced by lipopolysaccharide (LPS)." | 3.76 | PPARγ agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways. ( Aiguo, S; Ji, H; Li, X; Wang, H; Xiang, L; Zhang, F, 2010) |
| "Samples from a previous prospective, randomized study comparing the effects of pioglitazone with simvastatin on chronic systemic inflammation were measured at baseline and endpoint with both tests." | 3.75 | Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study. ( Armbruster, FP; Efstrathios, K; Forst, T; Hanefeld, M; Löbig, M; Pfützner, A, 2009) |
| " In impaired glucose tolerance subjects, these procedures were performed before and after treatment with pioglitazone or metformin." | 3.74 | Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. ( Bodles, AM; Fried, SK; Kern, LM; Kern, PA; Lee, MJ; McGehee, RE; Phanavanh, B; Rasouli, N; Spencer, HJ; Starks, T; Varma, V; Yao-Borengasser, A, 2007) |
| " Pioglitazone has antiatherogenic property through the inhibition of inflammation." | 3.74 | Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting. ( Daida, H; Ikeda, E; Kajimoto, K; Kasai, T; Kubota, N; Miyauchi, K; Sumiyoshi, K; Yokoyama, T, 2008) |
| "To determine whether peroxisome proliferator-activated receptor (PPAR) gamma ligands improve survival of patients with septic shock we treated a mouse model of sepsis [apolipoprotein (Apo) E) knockout mice] with pioglitazone, a PPAR-gamma ligand." | 3.74 | Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis. ( Haraguchi, G; Imai, T; Isobe, M; Kosuge, H; Maejima, Y; Suzuki, J; Yoshida, M, 2008) |
| " We evaluated the effect of 24- to 48-h 8 microM l-805645 or 10 microM pioglitazone on 25 mM D-glucose-induced markers of fibrosis in HK-2 cells." | 3.73 | PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. ( Chen, X; Panchapakesan, U; Pollock, CA; Sumual, S, 2005) |
| " We investigated the effect of pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on dextran sulfate sodium-induced colonic mucosal injury and inflammation in mice." | 3.71 | Pioglitazone, a PPAR-gamma ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-kappaB-cytokine cascade. ( Handa, O; Ichikawa, H; Naito, Y; Takagi, T; Tomatsuri, N; Yoshida, N; Yoshikawa, T, 2002) |
| "While vitamin E has shown to improve nonalcoholic steatohepatitis (NASH) in patients without diabetes, information on patients with type 2 diabetes mellitus (T2DM) is lacking." | 2.90 | Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. ( Biernacki, DM; Bril, F; Cusi, K; Hecht, J; Kalavalapalli, S; Lai, J; Lomonaco, R; Orsak, BK; Subbarayan, SK; Suman, A; Tio, F, 2019) |
| "Fenofibrate was shown to increase serum sirtuin 1 and decrease serum fetuin A levels in obese patients." | 2.80 | Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis. ( Abd El-Razek, RS; El-Hefnawy, MH; El-Mesallamy, HO; Noureldein, MH, 2015) |
| "Chronic low-grade inflammation is a common feature of insulin resistant states, including obesity and type 2 diabetes." | 2.78 | Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. ( Aroda, V; Ciaraldi, TP; Henry, RR; Mudaliar, SR, 2013) |
| "Pioglitazone-treated patients were found to have statistically significantly larger decreases in mean CRP levels (-0." | 2.78 | Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes. ( Ceriello, A; De Berardis, G; Evangelista, V; Genovese, S; Mannucci, E; Nicolucci, A; Pellegrini, F; Totani, L, 2013) |
| "Pioglitazone has demonstrated a favorable CV profile relative to other oral antidiabetic drugs (OADs) in outcome and observational studies." | 2.75 | Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. ( Arora, V; Jacks, R; Perez, A; Spanheimer, R, 2010) |
| "Obesity is a low grade inflammatory state associated with premature cardiovascular morbidity and mortality." | 2.73 | Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. ( McCance, DR; McMahon, R; Powell, L; Ryan, KE; Trimble, ER, 2007) |
| "Thirty subjects with type 2 diabetes were initiated on intensive insulin therapy (continuous subcutaneous insulin infusion [n = 12] or multiple daily injections [n = 18]) and then randomized to either pioglitazone (PIO group;45 mg/day), ramipril (RAM group; 10 mg/day), or placebo (PLC group) for 36 weeks." | 2.73 | Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. ( Cersosimo, E; Cusi, K; DeFronzo, R; Fernandez, M; Musi, N; Sriwijilkamol, AA; Triplitt, C; Wajcberg, E, 2008) |
| "Pioglitazone has shown promise in secondary stroke prevention for insulin-resistant patients; however, its use is not yet widespread." | 2.72 | Diabetes, stroke, and neuroresilience: looking beyond hyperglycemia. ( Krinock, MJ; Singhal, NS, 2021) |
| "Inflammation is implicated in the development and severity of the coronavirus disease 2019 (COVID-19), as well as in the pathophysiology of diabetes." | 2.66 | Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era? ( Ferrannini, E; Katsiki, N, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) affects one-third of the population worldwide, of which a substantial number of patients suffer from non-alcoholic steatohepatitis (NASH)." | 2.61 | Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. ( Boeckmans, J; Buyl, K; De Kock, J; M Rodrigues, R; Natale, A; Rogiers, V; Rombaut, M; Vanhaecke, T, 2019) |
| "Nonalcoholic fatty liver disease (NAFLD), the most prevalent cause of chronic liver disease worldwide, is strongly associated with obesity and insulin resistance." | 2.61 | Nonalcoholic Fatty Liver Disease and Obesity Treatment. ( Brunner, KT; Henneberg, CJ; Long, MT; Wilechansky, RM, 2019) |
| "Depression is a common comorbidity in diabetes but conventional antidepressant treatments do not consistently improve outcomes." | 2.58 | Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials. ( Hopkins, CWP; Ismail, K; Moulton, CD; Stahl, D, 2018) |
| "It also provides an overview of NAFLD agents currently under development." | 2.55 | Current and future pharmacologic treatment of nonalcoholic steatohepatitis. ( Banini, BA; Sanyal, AJ, 2017) |
| "As rosiglitazone has recently been linked to a higher risk of heart failure, stroke, and all-cause mortality in old patients, it has been interrupted from the European market." | 2.50 | Modulatory effects of peroxisome proliferator-activated receptor-γ on CXCR3 chemokines. ( Antonelli, A; Di Domenicantonio, A; Fallahi, P; Ferrari, SM; Ferri, C; Manfredi, A, 2014) |
| "Insulin resistance is a principal underlying defect in type 2 DM along with beta-cell dysfunction, and this insulin resistance underpins many of the abnormalities associated with the metabolic syndrome." | 2.43 | The Clinical Significance of PPAR Gamma Agonism. ( Campbell, IW, 2005) |
| "Inflammation is known to have a pathogenic role in atherosclerosis and the genesis of acute coronary syndromes." | 2.43 | Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. ( Gil-Ortega, I; Kaski, JC; Marzoa-Rivas, R; Ríos-Vázquez, R, 2006) |
| "Pioglitazone also mitigated most of the steatohepatitis-related changes, however, memantine was more effective in most of the studied parameters." | 1.91 | A novel approach to repositioning memantine for metabolic syndrome-induced steatohepatitis: Modulation of hepatic autophagy, inflammation, and fibrosis. ( Abdel-Ghanyª, RH; Alsemehᵇ, AE; Elgharbawyª, AS; Metwallyª, SS; Zakariaª, EM, 2023) |
| "Tamoxifen (TAM) is a chemotherapeutic drug widely utilized to treat breast cancer." | 1.91 | Pioglitazone attenuates tamoxifen-induced liver damage in rats via modulating Keap1/Nrf2/HO-1 and SIRT1/Notch1 signaling pathways: In-vivo investigations, and molecular docking analysis. ( Elariny, HA; Kamel, GAM, 2023) |
| " These beneficial effects of VIT D may expand its use by diabetics combined with antidiabetic drugs due to its anti-inflammatory, antioxidant, and antiapoptotic properties." | 1.72 | Vitamin D Combined with Pioglitazone Mitigates Type-2 Diabetes-induced Hepatic Injury Through Targeting Inflammation, Apoptosis, and Oxidative Stress. ( Elyamany, MF; Hamouda, HA; Mansour, SM, 2022) |
| "Inflammation is a biological response of the immune system, which can be triggered by many factors, including pathogens." | 1.72 | PPARγ regulates the expression of genes involved in the DNA damage response in an inflamed endometrium. ( Bogacka, I; Golubska, M; Jastrzębski, JP; Kunicka, Z; Kurzyńska, A; Makowczenko, KG; Mierzejewski, K; Paukszto, Ł, 2022) |
| "Major disease phenotypes include: adrenomyeloneuropathy (AMN), progressive spinal cord axonal degeneration, and cerebral ALD (C-ALD), inflammatory white matter demyelination and degeneration." | 1.72 | Therapeutic potential of deuterium-stabilized (R)-pioglitazone-PXL065-for X-linked adrenoleukodystrophy. ( DeWitt, S; Hallakou-Bozec, S; Jacques, V; Kaur, N; Klett, E; Moller, DE; Monternier, PA; Nagaraja, TN; Parasar, P; Singh, J; Theurey, P, 2022) |
| "Pioglitazone treatment was associated with increased expression of chemokine (Cxcl1, Cxcl2, and Ccl20) and cytokine genes (Tnfa, Il6, and Cfs3) in bronchial brushes obtained 6 h after infection." | 1.72 | The PPAR-γ agonist pioglitazone exerts proinflammatory effects in bronchial epithelial cells during acute Pseudomonas aeruginosa pneumonia. ( de Vos, AF; Ferreira, BL; Otto, NA; Ramirez-Moral, I; Salomão, R; van der Poll, T, 2022) |
| "Valvular inflammation triggered by hyperlipidemia has been considered as an important initial process of aortic valve disease; however, cellular and molecular evidence remains unclear." | 1.72 | Single-cell transcriptomics reveal cellular diversity of aortic valve and the immunomodulation by PPARγ during hyperlipidemia. ( Ahn, HS; Ann, SJ; Choi, JH; Chung, J; Go, DM; Han, I; Jeong, SC; Kim, DY; Kim, K; Kim, KW; Kim, M; Kim, N; Kim, TK; Lee, HO; Lee, S; Lee, SH; Lee, SP; Oh, GT; Park, J; Park, JH; Park, KS; Park, SE; Park, WY; Shim, D; Woo, SH; Yoon, WK; Zhang, JY, 2022) |
| "Rats were tested for thermal hyperalgesia and mechanical allodynia." | 1.56 | Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: Targeting Nav1.7 channels and PPAR-γ. ( El-Gawly, HW; El-Sherbeeny, NA; Elaidy, SM; Elkholy, SE; Toraih, EA, 2020) |
| "Ischemia reperfusion injury (IRI) during liver-metastasis resection for treatment of colon cancer may increase the risk of further metastasis." | 1.56 | Ischemia reperfusion-induced metastasis is resistant to PPARγ agonist pioglitazone in a murine model of colon cancer. ( Aoki, T; Bouvet, M; Fukuda, Y; Higuchi, T; Hoffman, RM; Inubushi, S; Murakami, M; Nishino, H; Singh, SR; Sugisawa, N; Tashiro, Y; Yamamoto, J, 2020) |
| "Treatment with pioglitazone, BCP, BCP + CB2R antagonist, AM630, or BCP + PPAR-γ antagonist, BADGE was started from the 9th week and continued till the 12th week." | 1.51 | Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: Involvement of CB2 and PPAR-γ receptors. ( El-Fayoumi, HM; Mahmoud, MF; Youssef, DA, 2019) |
| "Pioglitazone (PGZ) is a peroxisome proliferator-activated receptor agonist." | 1.51 | Nanoemulsion strategy of pioglitazone for the treatment of skin inflammatory diseases. ( Calpena, AC; Clares, B; Espinoza, LC; Fábrega, MJ; Garduño-Ramírez, ML; Rodríguez-Lagunas, MJ; Silva-Abreu, M, 2019) |
| "Treatment with pioglitazone, significantly attenuated the postnatal propionic acid-induced social impairment, repetitive behavior, hyperactivity, anxiety and low exploratory activity." | 1.51 | A selective peroxisome proliferator-activated receptor-γ agonist benefited propionic acid induced autism-like behavioral phenotypes in rats by attenuation of neuroinflammation and oxidative stress. ( Mirza, R; Sharma, B, 2019) |
| "Atherosclerosis was induced via a high-cholesterol diet and endothelial denudation." | 1.48 | Effect of pioglitazone on inflammation and calcification in atherosclerotic rabbits : An ( Feng, T; Li, J; Nie, M; Xu, J; Xu, Z; Yan, Y; Zhang, M; Zhao, Q; Zhao, X, 2018) |
| "Treatment with pioglitazone reduced the density of CLS in periprostatic fat and suppressed levels of TNFα, TGFβ, and the chemokine monocyte chemoattractant protein-1 (MCP-1)." | 1.48 | Pioglitazone Inhibits Periprostatic White Adipose Tissue Inflammation in Obese Mice. ( Bhardwaj, P; Dannenberg, AJ; Falcone, DJ; Giri, DD; Miyazawa, M; Subbaramaiah, K; Wang, H; Zhou, XK, 2018) |
| "Pioglitazone could enhance alternative activation of monocyte-derived macrophages and consequently immunomodulation in these patients." | 1.46 | Immunomodulation in systemic lupus erythematosus: induction of M2 population in monocyte-derived macrophages by pioglitazone. ( Memarian, A; Mohammadi, S; Saghaeian-Jazi, M; Sedighi, S, 2017) |
| "Pioglitazone (PGZ) is an agonist of peroxisome proliferator-activated receptors (PPARs), a nuclear receptor that regulates important cellular functions, including inflammatory responses." | 1.46 | Human Skin Permeation Studies with PPARγ Agonist to Improve Its Permeability and Efficacy in Inflammatory Processes. ( Calpena, AC; Espina, M; Espinoza, LC; Fábrega, MJ; García, ML; Rodríguez-Lagunas, MJ; Silva-Abreu, M, 2017) |
| "Inflammation is a known risk factor in diabetes." | 1.43 | Pioglitazone alleviates inflammation in diabetic mice fed a high-fat diet via inhibiting advanced glycation end-product-induced classical macrophage activation. ( Ge, J; Jin, X; Liu, L; Shen, C; Yao, T; Zhou, Z, 2016) |
| "Pioglitazone was generally more effective than vildagliptin in the studied parameters except for the lipid profile where the effect of both drugs was comparable and for the liver enzymes and renal parameters where vildagliptin was more effective." | 1.43 | Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats. ( El Sarha, A; Refaat, R; Sakr, A; Salama, M, 2016) |
| "Diabetic hyperglycemia has been suggested to play a role in osteoarthritis." | 1.42 | PPARγ is involved in the hyperglycemia-induced inflammatory responses and collagen degradation in human chondrocytes and diabetic mouse cartilages. ( Chan, DC; Chao, SC; Chen, CM; Chen, YJ; Lan, KC; Liu, SH; Tsai, KS; Wang, CC; Yang, RS, 2015) |
| "Unlike tumors, the RAW264." | 1.42 | The effect of PPAR-γ agonist on (18)F-FDG PET imaging for differentiating tumors and inflammation lesions. ( Cheong, SJ; Jeong, HJ; Kim, EM; Lee, CM; Lim, ST; Sohn, MH, 2015) |
| "Ipragliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that increases urinary glucose excretion by inhibiting renal glucose reabsorption and thereby causes a subsequent antihyperglycemic effect." | 1.42 | Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. ( Hayashizaki-Someya, Y; Koide, K; Kurosaki, E; Mitori, H; Takakura, S; Takasu, T; Yamazaki, S, 2015) |
| "Non-alcoholic fatty liver disease (NAFLD) defines a wide spectrum of liver diseases that extends from simple steatosis to non-alcoholic steatohepatitis." | 1.42 | LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD). ( Costa Oliveira, A; de Lima, Mdo C; de Oliveira Cipriano Torres, D; dos Santos Gomes, FO; dos Santos Silva, B; dos Santos, LA; Lima Ribeiro, E; Peixoto, CA; Pitta, Ida R; Soares e Silva, AK, 2015) |
| "Hyperglycemia was induced by streptozotocin treatment." | 1.42 | Hyperglycemia and PPARγ Antagonistically Influence Macrophage Polarization and Infarct Healing After Ischemic Stroke. ( Gliem, M; Hartung, HP; Jander, S; Klotz, L; van Rooijen, N, 2015) |
| "PPAR-γ protein and gene expression in COPD alveolar macrophages was compared with control smokers and never-smokers." | 1.40 | The effect of peroxisome proliferator-activated receptor-γ ligands on in vitro and in vivo models of COPD. ( Fox, JC; Lea, S; Metcalfe, H; Plumb, J; Singh, D; Spicer, D; Woodman, P, 2014) |
| "Pioglitazone treatment increased the cross-sectional area of adipocytes by 18% (p = 0." | 1.40 | Pioglitazone treatment reduces adipose tissue inflammation through reduction of mast cell and macrophage number and by improving vascularity. ( Adu, A; Finlin, BS; Kern, PA; Peterson, CA; Rasouli, N; Shipp, LR; Spencer, M; Yang, L; Zhu, B, 2014) |
| "Adjuvant arthritis was induced by single intra-dermal injection of 0." | 1.39 | Anti-arthritic and anti-inflammatory activity of combined pioglitazone and prednisolone on adjuvant-induced arthritis. ( Banerjee, BD; Mediratta, PK; Negi, H; Sharma, KK; Suke, SG, 2013) |
| " VSMCs were treated in a dose-response manner with insulin (0, 1, 10, and 100 nM) for 20 min, and Akt and Erk phosphorylation were measured by Western blot analysis." | 1.38 | Potential role of insulin signaling on vascular smooth muscle cell migration, proliferation, and inflammation pathways. ( Cersosimo, E; Musi, N; Xu, X, 2012) |
| "Here, we expanded MSs from human breast cancer and normal mammary gland tissues, as well from tumorigenic (MCF7) and non-tumorigenic (MCF10) breast cell lines." | 1.38 | Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. ( Avenia, N; Bonafé, M; Ceccarelli, C; De Carolis, S; Guarnieri, T; Orlandi, M; Papi, A; Sanguinetti, A; Santini, D; Sidoni, A; Storci, G; Taffurelli, M, 2012) |
| "Pioglitazone-treated monkeys also showed a dose-dependent modulation of CD68-ir inflammatory cells, that was significantly decreased for 5 mg/kg treated animals compared to placebo (P = 0." | 1.37 | The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. ( Bondarenko, V; Brunner, K; Emborg, ME; Joers, V; Johnson, JA; Kemnitz, JW; Simmons, HA; Swanson, CR; Ziegler, TE, 2011) |
| "Inflammation is an essential component of vulnerable or high-risk atheromas." | 1.37 | Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. ( Calcagno, C; Dickson, SD; Fayad, ZA; Fisher, EA; Fuster, V; Hayashi, K; Lin, J; Moon, MJ; Moshier, E; Mounessa, JS; Nicolay, K; Roytman, M; Rudd, JH; Tsimikas, S; Vucic, E, 2011) |
| "Hyperinsulinemia is associated with enhanced MMP-9 serum levels, potentially facilitating monocyte migration to and infiltration of adipose tissue and the arterial wall, thereby contributing to the increased cardiovascular risk in obese, hyperinsulinemic patients." | 1.35 | Insulin facilitates monocyte migration: a possible link to tissue inflammation in insulin-resistance. ( Clemenz, M; Fleck, E; Graf, K; Kappert, K; Kintscher, U; Meyborg, H; Stawowy, P, 2008) |
| "Pioglitazone treatment of KK-A(y) mice for 14 days significantly reduced the accumulation of inflammatory cells in ischemic myocardium, and infarct size 3 days after reperfusion compared to vehicle treatment (p<0." | 1.35 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. ( Fuchigami, S; Hayasaki, T; Honda, T; Kaikita, K; Matsukawa, M; Ogawa, H; Sakashita, N; Sugiyama, S; Takeya, M; Tsujita, K, 2008) |
| "Pioglitazone treatment significantly inhibited hepatic I/R injury as determined by serological and histological analyses." | 1.34 | Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice. ( Akahori, T; Enomoto, K; Hamada, K; Kanehiro, H; Kuzumoto, Y; Nakajima, Y; Nakamura, S; Nomi, T; Sho, M; Suzaki, Y, 2007) |
| "Patients with diabetic nephropathy have a high rate of cardiovascular events and mortality." | 1.33 | Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. ( Agarwal, R, 2006) |
| "Because coronary artery disease is a major complication for such patients, it is important to determine the effects of PPARgamma activation on arteriosclerosis." | 1.31 | Antiinflammatory and antiarteriosclerotic effects of pioglitazone. ( Egashira, K; Hiasa, K; Ichiki, T; Inoue, S; Ishibashi, M; Kitamoto, S; Ni, W; Takeshita, A; Usui, M; Zhao, Q, 2002) |
| "Pioglitazone was given to the rats by gastric intubation 1 h before the aspirin administration." | 1.31 | Pioglitazone, a specific PPAR-gamma ligand, inhibits aspirin-induced gastric mucosal injury in rats. ( Matsuyama, K; Naito, Y; Takagi, T; Yoshida, N; Yoshikawa, T, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 41 (23.03) | 29.6817 |
| 2010's | 101 (56.74) | 24.3611 |
| 2020's | 36 (20.22) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Hamouda, HA | 1 |
| Mansour, SM | 1 |
| Elyamany, MF | 2 |
| Liu, SY | 1 |
| Huang, CC | 1 |
| Huang, SF | 1 |
| Liao, TL | 1 |
| Kuo, NR | 1 |
| Yang, YY | 1 |
| Li, TH | 1 |
| Liu, CW | 1 |
| Hou, MC | 1 |
| Lin, HC | 1 |
| Colca, JR | 1 |
| Scherer, PE | 2 |
| Mierzejewski, K | 2 |
| Paukszto, Ł | 2 |
| Kurzyńska, A | 2 |
| Kunicka, Z | 2 |
| Jastrzębski, JP | 2 |
| Makowczenko, KG | 1 |
| Golubska, M | 1 |
| Bogacka, I | 2 |
| Monternier, PA | 1 |
| Singh, J | 1 |
| Parasar, P | 1 |
| Theurey, P | 1 |
| DeWitt, S | 1 |
| Jacques, V | 1 |
| Klett, E | 1 |
| Kaur, N | 1 |
| Nagaraja, TN | 1 |
| Moller, DE | 1 |
| Hallakou-Bozec, S | 1 |
| Ferreira, BL | 2 |
| Ramirez-Moral, I | 2 |
| Otto, NA | 1 |
| Salomão, R | 1 |
| de Vos, AF | 2 |
| van der Poll, T | 2 |
| Li, L | 2 |
| Pan, G | 1 |
| Fan, R | 1 |
| Li, D | 2 |
| Guo, L | 1 |
| Ma, L | 1 |
| Liang, H | 1 |
| Qiu, J | 1 |
| Li, XF | 1 |
| Yin, SQ | 1 |
| Li, H | 1 |
| Yang, YL | 1 |
| Chen, X | 2 |
| Song, B | 1 |
| Wu, S | 1 |
| Wu, YY | 1 |
| Wang, H | 4 |
| Li, J | 2 |
| Guo, Y | 1 |
| Zuo, W | 1 |
| Yin, L | 1 |
| Gu, T | 1 |
| Wang, S | 1 |
| Fang, Z | 1 |
| Wang, B | 2 |
| Dong, H | 1 |
| Hou, W | 1 |
| Zuo, Z | 1 |
| Deng, J | 1 |
| Shaaban, HH | 1 |
| Alzaim, I | 1 |
| El-Mallah, A | 1 |
| Aly, RG | 1 |
| El-Yazbi, AF | 3 |
| Wahid, A | 1 |
| Lee, SH | 3 |
| Kim, N | 1 |
| Kim, M | 1 |
| Woo, SH | 1 |
| Han, I | 1 |
| Park, J | 1 |
| Kim, K | 3 |
| Park, KS | 1 |
| Shim, D | 1 |
| Park, SE | 1 |
| Zhang, JY | 1 |
| Go, DM | 1 |
| Kim, DY | 1 |
| Yoon, WK | 1 |
| Lee, SP | 1 |
| Chung, J | 1 |
| Kim, KW | 1 |
| Park, JH | 1 |
| Lee, S | 1 |
| Ann, SJ | 1 |
| Ahn, HS | 1 |
| Jeong, SC | 1 |
| Kim, TK | 1 |
| Oh, GT | 1 |
| Park, WY | 1 |
| Lee, HO | 1 |
| Choi, JH | 1 |
| da Rocha, GHO | 1 |
| Loiola, RA | 1 |
| de Paula-Silva, M | 1 |
| Shimizu, F | 1 |
| Kanda, T | 1 |
| Vieira, A | 1 |
| Gosselet, F | 1 |
| Farsky, SHP | 1 |
| Sanyal, AJ | 3 |
| Williams, SA | 2 |
| Lavine, JE | 2 |
| Neuschwander-Tetri, BA | 2 |
| Alexander, L | 2 |
| Ostroff, R | 2 |
| Biegel, H | 2 |
| Kowdley, KV | 2 |
| Chalasani, N | 2 |
| Dasarathy, S | 2 |
| Diehl, AM | 2 |
| Loomba, R | 2 |
| Hameed, B | 2 |
| Behling, C | 2 |
| Kleiner, DE | 2 |
| Karpen, SJ | 2 |
| Williams, J | 2 |
| Jia, Y | 2 |
| Yates, KP | 2 |
| Tonascia, J | 2 |
| Turosz, N | 1 |
| Chęcińska, K | 1 |
| Chęciński, M | 1 |
| Kamińska, M | 1 |
| Nowak, Z | 1 |
| Sikora, M | 1 |
| Chlubek, D | 1 |
| McClelland, TJ | 1 |
| Fowler, AJ | 1 |
| Davies, TW | 1 |
| Pearse, R | 1 |
| Prowle, J | 1 |
| Puthucheary, Z | 1 |
| Zakariaª, EM | 1 |
| Abdel-Ghanyª, RH | 1 |
| Elgharbawyª, AS | 1 |
| Alsemehᵇ, AE | 1 |
| Metwallyª, SS | 1 |
| Onursal, C | 1 |
| Reel, B | 1 |
| Bintepe, C | 1 |
| Guzeloglu, M | 1 |
| Ersoy, N | 1 |
| Bagriyanik, A | 1 |
| Ghasemi, SZ | 1 |
| Beigoli, S | 1 |
| Memarzia, A | 1 |
| Behrouz, S | 1 |
| Gholamnezhad, Z | 1 |
| Darroudi, M | 1 |
| Amin, F | 1 |
| Boskabady, MH | 1 |
| Hussein, S | 1 |
| Kamel, GAM | 2 |
| Shlykova, O | 1 |
| Izmailova, O | 1 |
| Kabaliei, A | 1 |
| Palchyk, V | 1 |
| Shynkevych, V | 1 |
| Kaidashev, I | 1 |
| Alhowail, AH | 1 |
| Cinakova, A | 1 |
| Krenek, P | 1 |
| Klimas, J | 1 |
| Kralova, E | 1 |
| Elariny, HA | 1 |
| Elkhatib, MAW | 1 |
| Mroueh, A | 2 |
| Rafeh, RW | 1 |
| Sleiman, F | 1 |
| Fouad, H | 1 |
| Saad, EI | 1 |
| Fouda, MA | 1 |
| Elgaddar, O | 1 |
| Issa, K | 1 |
| Eid, AH | 2 |
| Eid, AA | 1 |
| Abd-Elrahman, KS | 1 |
| Bril, F | 2 |
| Barb, D | 1 |
| Lomonaco, R | 2 |
| Lai, J | 2 |
| Cusi, K | 3 |
| Wu, Y | 1 |
| Zhang, Y | 4 |
| Dai, L | 1 |
| Wang, Q | 2 |
| Xue, L | 2 |
| Su, Z | 1 |
| Zhang, C | 1 |
| Boeckmans, J | 1 |
| Natale, A | 1 |
| Rombaut, M | 1 |
| Buyl, K | 1 |
| Rogiers, V | 1 |
| De Kock, J | 1 |
| Vanhaecke, T | 1 |
| M Rodrigues, R | 1 |
| Elkholy, SE | 1 |
| Elaidy, SM | 1 |
| El-Sherbeeny, NA | 1 |
| Toraih, EA | 1 |
| El-Gawly, HW | 1 |
| Liu, WC | 1 |
| Wu, CW | 1 |
| Fu, MH | 1 |
| Tain, YL | 1 |
| Liang, CK | 1 |
| Hung, CY | 1 |
| Chen, IC | 1 |
| Lee, YC | 2 |
| Wu, CY | 1 |
| Wu, KLH | 1 |
| Carboni, E | 2 |
| Carta, AR | 1 |
| Qin, X | 1 |
| Wang, W | 1 |
| Wu, H | 1 |
| Liu, D | 1 |
| Wang, R | 2 |
| Xu, J | 2 |
| Jiang, H | 1 |
| Pan, F | 1 |
| Bakkar, NZ | 1 |
| Mougharbil, N | 1 |
| Kaplan, A | 1 |
| Fares, S | 1 |
| Zouein, FA | 1 |
| Katsiki, N | 1 |
| Ferrannini, E | 1 |
| Tashiro, Y | 1 |
| Nishino, H | 1 |
| Higuchi, T | 1 |
| Sugisawa, N | 1 |
| Fukuda, Y | 2 |
| Yamamoto, J | 1 |
| Inubushi, S | 1 |
| Aoki, T | 1 |
| Murakami, M | 1 |
| Singh, SR | 1 |
| Bouvet, M | 1 |
| Hoffman, RM | 1 |
| Abd El Fattah, MA | 1 |
| Abdelhamid, YA | 1 |
| Badary, OA | 1 |
| Heikal, OA | 1 |
| Krinock, MJ | 1 |
| Singhal, NS | 1 |
| Drygalski, K | 1 |
| Fereniec, E | 1 |
| Zalewska, A | 1 |
| Krętowski, A | 1 |
| Żendzian-Piotrowska, M | 1 |
| Maciejczyk, M | 1 |
| Banini, BA | 1 |
| Mohammadi, S | 1 |
| Saghaeian-Jazi, M | 1 |
| Sedighi, S | 1 |
| Memarian, A | 1 |
| Peymani, M | 1 |
| Ghaedi, K | 1 |
| Hashemi, MS | 1 |
| Ghoochani, A | 1 |
| Kiani-Esfahani, A | 1 |
| Nasr-Esfahani, MH | 1 |
| Baharvand, H | 1 |
| Bernardo, A | 1 |
| Giammarco, ML | 1 |
| De Nuccio, C | 1 |
| Ajmone-Cat, MA | 1 |
| Visentin, S | 1 |
| De Simone, R | 1 |
| Minghetti, L | 1 |
| Deng, W | 1 |
| Meng, Z | 1 |
| Sun, A | 1 |
| Yang, Z | 1 |
| Nie, M | 1 |
| Xu, Z | 1 |
| Zhang, M | 1 |
| Yan, Y | 1 |
| Feng, T | 1 |
| Zhao, X | 1 |
| Zhao, Q | 2 |
| Silva-Abreu, M | 2 |
| Espinoza, LC | 2 |
| Rodríguez-Lagunas, MJ | 2 |
| Fábrega, MJ | 2 |
| Espina, M | 1 |
| García, ML | 1 |
| Calpena, AC | 2 |
| Pane, B | 1 |
| Gazzola, V | 1 |
| Spinella, G | 1 |
| Bagnato, P | 1 |
| Grillo, F | 1 |
| Vellone, VG | 1 |
| Palombo, D | 1 |
| Miyazawa, M | 1 |
| Subbaramaiah, K | 1 |
| Bhardwaj, P | 1 |
| Zhou, XK | 1 |
| Falcone, DJ | 1 |
| Giri, DD | 1 |
| Dannenberg, AJ | 1 |
| Xia, JY | 1 |
| Sun, K | 1 |
| Hepler, C | 1 |
| Ghaben, AL | 1 |
| Gupta, RK | 1 |
| An, YA | 1 |
| Holland, WL | 1 |
| Morley, TS | 1 |
| Adams, AC | 1 |
| Gordillo, R | 1 |
| Kusminski, CM | 1 |
| Moulton, CD | 1 |
| Hopkins, CWP | 1 |
| Ismail, K | 1 |
| Stahl, D | 1 |
| Okada, K | 1 |
| Hosooka, T | 1 |
| Shinohara, M | 1 |
| Ogawa, W | 1 |
| Youssef, DA | 1 |
| El-Fayoumi, HM | 1 |
| Mahmoud, MF | 1 |
| Daniels, SJ | 1 |
| Leeming, DJ | 1 |
| Detlefsen, S | 1 |
| Bruun, MF | 1 |
| Hjuler, ST | 1 |
| Henriksen, K | 1 |
| Hein, P | 1 |
| Karsdal, MA | 1 |
| Brockbank, S | 1 |
| Cruwys, S | 1 |
| Zhang, X | 1 |
| Li, N | 1 |
| Lu, L | 1 |
| Lin, Q | 1 |
| Dong, P | 1 |
| Yang, B | 1 |
| Fei, J | 1 |
| Brunner, KT | 1 |
| Henneberg, CJ | 1 |
| Wilechansky, RM | 1 |
| Long, MT | 1 |
| Garduño-Ramírez, ML | 1 |
| Clares, B | 1 |
| Li, JM | 1 |
| Yu, R | 1 |
| Zhang, LP | 1 |
| Wen, SY | 1 |
| Wang, SJ | 1 |
| Zhang, XY | 1 |
| Xu, Q | 1 |
| Kong, LD | 1 |
| Biernacki, DM | 1 |
| Kalavalapalli, S | 1 |
| Subbarayan, SK | 1 |
| Tio, F | 1 |
| Suman, A | 1 |
| Orsak, BK | 1 |
| Hecht, J | 1 |
| Mirza, R | 1 |
| Sharma, B | 1 |
| Huang, H | 1 |
| Wang, ZJ | 1 |
| Zhang, HB | 1 |
| Liang, JX | 1 |
| Cao, WD | 1 |
| Wu, Q | 1 |
| He, CP | 1 |
| Chen, C | 2 |
| Lea, S | 1 |
| Plumb, J | 1 |
| Metcalfe, H | 1 |
| Spicer, D | 1 |
| Woodman, P | 1 |
| Fox, JC | 1 |
| Singh, D | 1 |
| Kim, H | 1 |
| Hwang, J | 1 |
| Park, S | 1 |
| Nahm, SF | 1 |
| Min, S | 1 |
| Lim, C | 1 |
| Park, K | 1 |
| Han, S | 1 |
| Ciaraldi, TP | 1 |
| Aroda, V | 1 |
| Mudaliar, SR | 1 |
| Henry, RR | 1 |
| Kaplan, J | 1 |
| Nowell, M | 1 |
| Chima, R | 1 |
| Zingarelli, B | 1 |
| Zhao, ZQ | 1 |
| Luo, R | 1 |
| Li, LY | 1 |
| Tian, FS | 1 |
| Zheng, XL | 1 |
| Xiong, HL | 1 |
| Sun, LT | 1 |
| Suke, SG | 1 |
| Negi, H | 1 |
| Mediratta, PK | 1 |
| Banerjee, BD | 1 |
| Sharma, KK | 1 |
| Uchiyama, M | 1 |
| Shimizu, A | 1 |
| Masuda, Y | 1 |
| Nagasaka, S | 1 |
| Takahashi, H | 1 |
| Takei, Y | 2 |
| Kim, MS | 1 |
| Yamamoto, Y | 1 |
| Kamei, N | 2 |
| Shimada, T | 1 |
| Liu, L | 2 |
| Moore, K | 1 |
| Woo, JR | 1 |
| Shoelson, SE | 2 |
| Lee, J | 2 |
| Schwabl, P | 1 |
| Payer, BA | 1 |
| Grahovac, J | 1 |
| Klein, S | 1 |
| Horvatits, T | 1 |
| Mitterhauser, M | 1 |
| Stift, J | 1 |
| Boucher, Y | 1 |
| Trebicka, J | 1 |
| Trauner, M | 1 |
| Angermayr, B | 1 |
| Fuhrmann, V | 1 |
| Reiberger, T | 1 |
| Peck-Radosavljevic, M | 1 |
| Papi, A | 2 |
| De Carolis, S | 2 |
| Bertoni, S | 1 |
| Storci, G | 2 |
| Sceberras, V | 1 |
| Santini, D | 2 |
| Ceccarelli, C | 2 |
| Taffurelli, M | 2 |
| Orlandi, M | 2 |
| Bonafé, M | 2 |
| Schmitt, MM | 1 |
| Fraemohs, L | 1 |
| Hackeng, TM | 1 |
| Weber, C | 1 |
| Koenen, RR | 1 |
| Ferrari, SM | 1 |
| Antonelli, A | 1 |
| Di Domenicantonio, A | 1 |
| Manfredi, A | 1 |
| Ferri, C | 1 |
| Fallahi, P | 1 |
| Spencer, M | 1 |
| Yang, L | 1 |
| Adu, A | 1 |
| Finlin, BS | 1 |
| Zhu, B | 1 |
| Shipp, LR | 1 |
| Rasouli, N | 3 |
| Peterson, CA | 1 |
| Kern, PA | 3 |
| Chen, YJ | 1 |
| Chan, DC | 1 |
| Lan, KC | 1 |
| Wang, CC | 1 |
| Chen, CM | 1 |
| Chao, SC | 1 |
| Tsai, KS | 1 |
| Yang, RS | 1 |
| Liu, SH | 1 |
| Cheong, SJ | 1 |
| Lee, CM | 1 |
| Kim, EM | 1 |
| Lim, ST | 1 |
| Sohn, MH | 1 |
| Jeong, HJ | 1 |
| Thal, SC | 1 |
| Neuhaus, W | 1 |
| Ibrahim, SM | 1 |
| El-Denshary, ES | 1 |
| Abdallah, DM | 1 |
| Hayashizaki-Someya, Y | 1 |
| Kurosaki, E | 1 |
| Takasu, T | 1 |
| Mitori, H | 1 |
| Yamazaki, S | 1 |
| Koide, K | 1 |
| Takakura, S | 1 |
| Zhang, MD | 1 |
| Zhao, XC | 1 |
| Zhang, YH | 1 |
| Yan, YF | 1 |
| Wang, ZM | 1 |
| Lv, SZ | 1 |
| Zhao, QM | 1 |
| Soares e Silva, AK | 1 |
| de Oliveira Cipriano Torres, D | 1 |
| dos Santos Gomes, FO | 1 |
| dos Santos Silva, B | 1 |
| Lima Ribeiro, E | 1 |
| Costa Oliveira, A | 1 |
| dos Santos, LA | 1 |
| de Lima, Mdo C | 1 |
| Pitta, Ida R | 1 |
| Peixoto, CA | 1 |
| Ma, C | 2 |
| Li, YQ | 1 |
| Cai, W | 1 |
| Zeng, YL | 1 |
| Boullu-Ciocca, S | 1 |
| Tassistro, V | 1 |
| Dutour, A | 1 |
| Grino, M | 1 |
| Noureldein, MH | 1 |
| Abd El-Razek, RS | 1 |
| El-Hefnawy, MH | 1 |
| El-Mesallamy, HO | 1 |
| Yamamoto, S | 1 |
| Zhong, J | 1 |
| Yancey, PG | 1 |
| Zuo, Y | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Yang, H | 1 |
| Narita, I | 1 |
| Kon, V | 1 |
| Gliem, M | 1 |
| Klotz, L | 1 |
| van Rooijen, N | 1 |
| Hartung, HP | 1 |
| Jander, S | 1 |
| Charkhpour, M | 1 |
| Ghavimi, H | 1 |
| Ghanbarzadeh, S | 1 |
| Yousefi, B | 1 |
| Khorrami, A | 1 |
| Mesgari, M | 1 |
| Hassanzadeh, K | 1 |
| Ying, W | 1 |
| Tseng, A | 1 |
| Chang, RC | 1 |
| Morin, A | 1 |
| Brehm, T | 1 |
| Triff, K | 1 |
| Nair, V | 1 |
| Zhuang, G | 1 |
| Song, H | 1 |
| Kanameni, S | 1 |
| Golding, MC | 1 |
| Bazer, FW | 1 |
| Chapkin, RS | 1 |
| Safe, S | 1 |
| Zhou, B | 1 |
| Simon, DK | 1 |
| Simuni, T | 1 |
| Elm, J | 1 |
| Clark-Matott, J | 1 |
| Graebner, AK | 1 |
| Baker, L | 1 |
| Dunlop, SR | 1 |
| Emborg, M | 1 |
| Kamp, C | 1 |
| Morgan, JC | 1 |
| Ross, GW | 1 |
| Sharma, S | 1 |
| Ravina, B | 1 |
| Byelan, OV | 1 |
| Borzykh, OA | 1 |
| Mamontova, TV | 1 |
| Kaidashev, IP | 1 |
| Du, J | 1 |
| Niu, X | 1 |
| Zhao, S | 1 |
| Kong, L | 1 |
| Nan, Y | 1 |
| Pinto, M | 1 |
| Nissanka, N | 1 |
| Peralta, S | 1 |
| Brambilla, R | 1 |
| Diaz, F | 1 |
| Moraes, CT | 1 |
| Jin, X | 1 |
| Zhou, Z | 1 |
| Ge, J | 1 |
| Yao, T | 1 |
| Shen, C | 1 |
| Wang, F | 1 |
| Liu, Y | 1 |
| Bi, Z | 1 |
| Liu, M | 2 |
| Bachstetter, AD | 1 |
| Cass, WA | 2 |
| Lifshitz, J | 1 |
| Bing, G | 2 |
| Houshmand, G | 1 |
| Mansouri, MT | 1 |
| Naghizadeh, B | 1 |
| Hemmati, AA | 1 |
| Hashemitabar, M | 1 |
| Refaat, R | 1 |
| Sakr, A | 1 |
| Salama, M | 1 |
| El Sarha, A | 1 |
| Sharma, M | 1 |
| Mohapatra, J | 1 |
| Malik, U | 1 |
| Nagar, J | 1 |
| Chatterjee, A | 1 |
| Ramachandran, B | 1 |
| Jain, MR | 1 |
| Corsini, I | 1 |
| Polvani, S | 1 |
| Tarocchi, M | 1 |
| Tempesti, S | 1 |
| Marroncini, G | 1 |
| Generoso, M | 1 |
| Bresci, C | 1 |
| Gozzini, E | 1 |
| Bianconi, T | 1 |
| Galli, A | 1 |
| Dani, C | 1 |
| Orasanu, G | 1 |
| Ziouzenkova, O | 1 |
| Devchand, PR | 1 |
| Nehra, V | 1 |
| Hamdy, O | 1 |
| Horton, ES | 1 |
| Plutzky, J | 2 |
| Kintscher, U | 2 |
| Hirano, M | 1 |
| Nakamura, T | 1 |
| Kitta, Y | 1 |
| Yano, T | 1 |
| Kobayashi, T | 2 |
| Sano, K | 1 |
| Fujioka, D | 1 |
| Saito, Y | 1 |
| Kodama, Y | 1 |
| Kawabata, K | 1 |
| Nakamura, K | 1 |
| Obata, JE | 1 |
| Kugiyama, K | 1 |
| Da Silva Morais, A | 1 |
| Lebrun, V | 1 |
| Abarca-Quinones, J | 1 |
| Brichard, S | 1 |
| Hue, L | 1 |
| Guigas, B | 1 |
| Viollet, B | 1 |
| Leclercq, IA | 1 |
| Toblli, JE | 1 |
| Ferrini, MG | 1 |
| Cao, G | 1 |
| Vernet, D | 1 |
| Angerosa, M | 1 |
| Gonzalez-Cadavid, NF | 1 |
| Nerla, R | 1 |
| Pitocco, D | 1 |
| Zaccardi, F | 1 |
| Scalone, G | 1 |
| Coviello, I | 1 |
| Mollo, R | 1 |
| Ghirlanda, G | 1 |
| Lanza, GA | 1 |
| Crea, F | 1 |
| Pasarica, M | 1 |
| Gowronska-Kozak, B | 1 |
| Burk, D | 1 |
| Remedios, I | 1 |
| Hymel, D | 1 |
| Gimble, J | 1 |
| Ravussin, E | 1 |
| Bray, GA | 1 |
| Smith, SR | 1 |
| Pfützner, A | 5 |
| Efstrathios, K | 1 |
| Löbig, M | 2 |
| Armbruster, FP | 1 |
| Hanefeld, M | 3 |
| Forst, T | 5 |
| Ao, C | 1 |
| Huo, Y | 1 |
| Qi, L | 1 |
| Xiong, Z | 1 |
| Qi, Y | 1 |
| Erdmann, E | 1 |
| Wilcox, R | 1 |
| Derosa, G | 3 |
| Maffioli, P | 3 |
| Salvadeo, SA | 3 |
| Ferrari, I | 3 |
| Ragonesi, PD | 2 |
| Querci, F | 2 |
| Franzetti, IG | 2 |
| Gadaleta, G | 2 |
| Ciccarelli, L | 2 |
| Piccinni, MN | 2 |
| D'Angelo, A | 3 |
| Cicero, AF | 2 |
| Blalock, EM | 1 |
| Phelps, JT | 1 |
| Pancani, T | 1 |
| Searcy, JL | 1 |
| Anderson, KL | 1 |
| Gant, JC | 1 |
| Popovic, J | 1 |
| Avdiushko, MG | 1 |
| Cohen, DA | 1 |
| Chen, KC | 1 |
| Porter, NM | 1 |
| Thibault, O | 1 |
| Ji, H | 1 |
| Zhang, F | 1 |
| Li, X | 2 |
| Xiang, L | 1 |
| Aiguo, S | 1 |
| Schöndorf, T | 3 |
| Mereu, R | 2 |
| Chang, K | 1 |
| Francis, SA | 1 |
| Aikawa, E | 1 |
| Figueiredo, JL | 1 |
| Kohler, RH | 1 |
| McCarthy, JR | 1 |
| Weissleder, R | 1 |
| Jaffer, FA | 1 |
| Fernandez-Boyanapalli, R | 1 |
| Frasch, SC | 1 |
| Riches, DW | 1 |
| Vandivier, RW | 1 |
| Henson, PM | 1 |
| Bratton, DL | 1 |
| Fogari, E | 1 |
| Gravina, A | 1 |
| Palumbo, I | 1 |
| Randazzo, S | 1 |
| Kume, O | 1 |
| Takahashi, N | 2 |
| Wakisaka, O | 1 |
| Nagano-Torigoe, Y | 1 |
| Teshima, Y | 1 |
| Nakagawa, M | 1 |
| Yufu, K | 1 |
| Hara, M | 1 |
| Saikawa, T | 1 |
| Yoshimatsu, H | 1 |
| Duffy, HS | 1 |
| Perez, A | 1 |
| Jacks, R | 1 |
| Arora, V | 1 |
| Spanheimer, R | 1 |
| Takemoto, M | 1 |
| Yokote, K | 1 |
| Gumieniczek, A | 1 |
| Komsta, L | 1 |
| Chehab, MR | 1 |
| Dohi, T | 1 |
| Miyauchi, K | 2 |
| Iesaki, T | 1 |
| Tsuruta, R | 1 |
| Tsuboi, S | 1 |
| Ogita, M | 1 |
| Kubota, N | 2 |
| Kasai, T | 2 |
| Yokoyama, T | 2 |
| Daida, H | 2 |
| Guo, N | 1 |
| Woeller, CF | 1 |
| Feldon, SE | 1 |
| Phipps, RP | 1 |
| Musholt, PB | 1 |
| Hohberg, C | 1 |
| Lehmann, U | 1 |
| Fuchs, W | 2 |
| Müller, J | 2 |
| Swanson, CR | 1 |
| Joers, V | 1 |
| Bondarenko, V | 1 |
| Brunner, K | 1 |
| Simmons, HA | 1 |
| Ziegler, TE | 1 |
| Kemnitz, JW | 1 |
| Johnson, JA | 1 |
| Emborg, ME | 1 |
| Dekordi, LA | 1 |
| Kleine, I | 1 |
| Vucic, E | 1 |
| Dickson, SD | 1 |
| Calcagno, C | 1 |
| Rudd, JH | 1 |
| Moshier, E | 1 |
| Hayashi, K | 1 |
| Mounessa, JS | 1 |
| Roytman, M | 1 |
| Moon, MJ | 1 |
| Lin, J | 1 |
| Tsimikas, S | 1 |
| Fisher, EA | 2 |
| Nicolay, K | 1 |
| Fuster, V | 1 |
| Fayad, ZA | 1 |
| Tawakol, A | 1 |
| Finn, AV | 1 |
| Mizoguchi, M | 1 |
| Tahara, N | 1 |
| Tahara, A | 1 |
| Nitta, Y | 1 |
| Kodama, N | 1 |
| Oba, T | 1 |
| Mawatari, K | 1 |
| Yasukawa, H | 1 |
| Kaida, H | 1 |
| Ishibashi, M | 2 |
| Hayabuchi, N | 1 |
| Harada, H | 1 |
| Ikeda, H | 1 |
| Yamagishi, S | 1 |
| Imaizumi, T | 1 |
| Marwick, TH | 1 |
| Narula, J | 1 |
| Yu, Y | 1 |
| Zhang, ZH | 1 |
| Wei, SG | 1 |
| Weiss, RM | 1 |
| Felder, RB | 1 |
| Wearn, JG | 1 |
| Suagee, JK | 1 |
| Crisman, MV | 1 |
| Corl, BA | 1 |
| Hulver, MW | 1 |
| Hodgson, DR | 1 |
| Geor, RJ | 1 |
| McCutcheon, LJ | 1 |
| Cersosimo, E | 2 |
| Xu, X | 1 |
| Musi, N | 2 |
| Nakatsuji, H | 1 |
| Kishida, K | 1 |
| Funahashi, T | 1 |
| Shimomura, I | 1 |
| Liu, CS | 1 |
| Chang, CC | 1 |
| Du, YC | 1 |
| Chang, FR | 1 |
| Wu, YC | 1 |
| Chang, WC | 1 |
| Hsieh, TJ | 1 |
| Guarnieri, T | 1 |
| Avenia, N | 1 |
| Sanguinetti, A | 1 |
| Sidoni, A | 1 |
| Kampoli, AM | 1 |
| Tousoulis, D | 1 |
| Pallantza, Z | 1 |
| Paterakis, G | 1 |
| Papageorgiou, N | 1 |
| Oikonomou, E | 1 |
| Miliou, A | 1 |
| Vlachopoulou, A | 1 |
| Stefanadis, C | 1 |
| Cipolletta, D | 1 |
| Feuerer, M | 1 |
| Li, A | 1 |
| Benoist, C | 1 |
| Mathis, D | 1 |
| Taguchi, K | 1 |
| Okada, A | 1 |
| Yasui, T | 1 |
| Ando, R | 1 |
| Tozawa, K | 1 |
| Kohri, K | 1 |
| Majer, O | 1 |
| Bourgeois, C | 1 |
| Zwolanek, F | 1 |
| Lassnig, C | 1 |
| Kerjaschki, D | 1 |
| Mack, M | 1 |
| Müller, M | 1 |
| Kuchler, K | 1 |
| Ohki, T | 1 |
| Isogawa, A | 1 |
| Iwamoto, M | 1 |
| Ohsugi, M | 1 |
| Yoshida, H | 2 |
| Toda, N | 1 |
| Tagawa, K | 1 |
| Omata, M | 1 |
| Koike, K | 1 |
| Yu, S | 1 |
| Li, MZ | 1 |
| Xu, H | 1 |
| Song, J | 1 |
| Lin, P | 1 |
| Zhang, L | 1 |
| Liu, Q | 1 |
| Huang, QX | 1 |
| Wang, K | 1 |
| Hou, WK | 1 |
| Genovese, S | 1 |
| De Berardis, G | 1 |
| Nicolucci, A | 1 |
| Mannucci, E | 1 |
| Evangelista, V | 1 |
| Totani, L | 1 |
| Pellegrini, F | 1 |
| Ceriello, A | 1 |
| Egashira, K | 1 |
| Hiasa, K | 1 |
| Inoue, S | 1 |
| Ni, W | 1 |
| Usui, M | 1 |
| Kitamoto, S | 1 |
| Ichiki, T | 1 |
| Takeshita, A | 1 |
| Takagi, T | 2 |
| Naito, Y | 2 |
| Tomatsuri, N | 1 |
| Handa, O | 1 |
| Ichikawa, H | 1 |
| Yoshida, N | 2 |
| Yoshikawa, T | 2 |
| Zafiriou, S | 1 |
| Stanners, SR | 1 |
| Polhill, TS | 1 |
| Poronnik, P | 1 |
| Pollock, CA | 2 |
| Schaefer, KL | 1 |
| Denevich, S | 1 |
| Cooley, SR | 1 |
| Nakajima, A | 1 |
| Wada, K | 1 |
| Schlezinger, J | 1 |
| Sherr, D | 1 |
| Saubermann, LJ | 1 |
| Panchapakesan, U | 1 |
| Sumual, S | 1 |
| Campbell, IW | 1 |
| Kim, SR | 1 |
| Lee, KS | 1 |
| Park, HS | 1 |
| Park, SJ | 1 |
| Min, KH | 1 |
| Jin, SM | 1 |
| Agarwal, R | 1 |
| Marx, N | 1 |
| Wöhrle, J | 1 |
| Nusser, T | 1 |
| Walcher, D | 1 |
| Rinker, A | 1 |
| Hombach, V | 1 |
| Koenig, W | 1 |
| Höher, M | 1 |
| Collino, M | 1 |
| Aragno, M | 1 |
| Mastrocola, R | 1 |
| Gallicchio, M | 1 |
| Rosa, AC | 1 |
| Dianzani, C | 1 |
| Danni, O | 1 |
| Thiemermann, C | 1 |
| Fantozzi, R | 1 |
| Trogan, E | 1 |
| Feig, JE | 1 |
| Dogan, S | 1 |
| Rothblat, GH | 1 |
| Angeli, V | 1 |
| Tacke, F | 1 |
| Randolph, GJ | 1 |
| Ríos-Vázquez, R | 1 |
| Marzoa-Rivas, R | 1 |
| Gil-Ortega, I | 1 |
| Kaski, JC | 1 |
| Varma, V | 2 |
| Yao-Borengasser, A | 2 |
| Bodles, AM | 2 |
| Phanavanh, B | 2 |
| Lee, MJ | 2 |
| Starks, T | 2 |
| Kern, LM | 2 |
| Spencer, HJ | 2 |
| McGehee, RE | 2 |
| Fried, SK | 2 |
| Ryan, KE | 1 |
| McCance, DR | 1 |
| Powell, L | 1 |
| McMahon, R | 1 |
| Trimble, ER | 1 |
| Hunter, RL | 1 |
| Dragicevic, N | 1 |
| Seifert, K | 1 |
| Choi, DY | 1 |
| Kim, HC | 1 |
| Sullivan, PG | 1 |
| Emanuele, E | 1 |
| Lossano, C | 1 |
| Politi, P | 1 |
| Barale, F | 1 |
| Rashidi, AA | 1 |
| Shikata, K | 1 |
| Fernandez, M | 1 |
| Triplitt, C | 1 |
| Wajcberg, E | 1 |
| Sriwijilkamol, AA | 1 |
| DeFronzo, R | 1 |
| Akahori, T | 1 |
| Sho, M | 1 |
| Hamada, K | 1 |
| Suzaki, Y | 1 |
| Kuzumoto, Y | 1 |
| Nomi, T | 1 |
| Nakamura, S | 1 |
| Enomoto, K | 1 |
| Kanehiro, H | 1 |
| Nakajima, Y | 1 |
| Kajimoto, K | 1 |
| Sumiyoshi, K | 1 |
| Ikeda, E | 1 |
| DU, RQ | 1 |
| Li, HL | 1 |
| Yang, WY | 1 |
| Xiao, JZ | 1 |
| Lou, DJ | 1 |
| Bai, XP | 1 |
| Pan, L | 1 |
| Kappert, K | 1 |
| Meyborg, H | 1 |
| Clemenz, M | 1 |
| Graf, K | 1 |
| Fleck, E | 1 |
| Stawowy, P | 1 |
| Ohman, MK | 1 |
| Shen, Y | 1 |
| Obimba, CI | 1 |
| Wright, AP | 1 |
| Warnock, M | 1 |
| Lawrence, DA | 1 |
| Eitzman, DT | 1 |
| Haraguchi, G | 1 |
| Kosuge, H | 1 |
| Maejima, Y | 1 |
| Suzuki, J | 1 |
| Imai, T | 1 |
| Yoshida, M | 1 |
| Isobe, M | 1 |
| Korantzopoulos, P | 1 |
| Goudevenos, JA | 1 |
| Liu, T | 1 |
| Li, G | 1 |
| Kimura, H | 1 |
| Torii, K | 1 |
| Okada, T | 1 |
| Fujii, H | 1 |
| Ishihara, S | 1 |
| Honda, T | 1 |
| Kaikita, K | 1 |
| Tsujita, K | 1 |
| Hayasaki, T | 1 |
| Matsukawa, M | 1 |
| Fuchigami, S | 1 |
| Sugiyama, S | 1 |
| Sakashita, N | 1 |
| Ogawa, H | 1 |
| Takeya, M | 1 |
| Karagiannis, E | 1 |
| Lübben, G | 1 |
| Roth, W | 1 |
| Grabellus, M | 1 |
| Flannery, M | 1 |
| Schaller, G | 1 |
| Kolodjaschna, J | 1 |
| Pleiner, J | 1 |
| Mittermayer, F | 1 |
| Kapiotis, S | 1 |
| Schmetterer, L | 1 |
| Wolzt, M | 1 |
| Matsuyama, K | 1 |
| Kon, K | 1 |
| Ikejima, K | 1 |
| Hirose, M | 1 |
| Yoshikawa, M | 1 |
| Enomoto, N | 1 |
| Kitamura, T | 1 |
| Sato, N | 1 |
| Diep, QN | 1 |
| El Mabrouk, M | 1 |
| Cohn, JS | 1 |
| Endemann, D | 1 |
| Amiri, F | 1 |
| Virdis, A | 1 |
| Neves, MF | 1 |
| Schiffrin, EL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Calisthenics Versus High-intensity Interval Exercises on Health-related Outcomes in Patients With Non-alcoholic Fatty Liver[NCT06032650] | 60 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | |||
| NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment[NCT01002547] | Phase 4 | 105 participants (Actual) | Interventional | 2010-06-24 | Completed | ||
| Effect of Low-Dose Pioglitazone in Patients With Nonalcoholic Steatohepatitis (NASH)[NCT04501406] | Phase 2 | 166 participants (Anticipated) | Interventional | 2020-12-15 | Recruiting | ||
| Comparison of the Effect of Fenofibrate Versus Curcumin in Type 2 Diabetic Patients Treated With Glimepiride[NCT04528212] | Phase 4 | 60 participants (Actual) | Interventional | 2020-11-01 | Completed | ||
| Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP): A Randomised Clinical Trial[NCT02347501] | Phase 2 | 118 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.[NCT01991197] | Phase 2 | 20 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases[NCT03693560] | Phase 4 | 80 participants (Actual) | Interventional | 2018-10-08 | Completed | ||
| Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213] | Phase 4 | 60 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| A Phase 3b, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Pioglitazone HCl and Metformin HCl Fixed-Dose Combination Therapy Compared to Pioglitazone HCl Monotherapy and to Metformin HCl Monotherapy in the Treatment of Subjects Wit[NCT00727857] | Phase 3 | 600 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT[NCT00722631] | 70 participants (Actual) | Interventional | 2007-05-31 | Completed | |||
| The Effects of the PPARy Agonist Rosiglitazone on Airway Hyperreactivity[NCT00614874] | Phase 2 | 16 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance[NCT00108615] | Phase 4 | 48 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Weight (in kg) / (Height [in m] x Height [in m]) (NCT01002547)
Timeframe: Month 18
| Intervention | kg/m2 (Mean) |
|---|---|
| Placebo | -0.6 |
| Vitamin E | 0.1 |
| Pioglitazone + Vitamin E | 1.4 |
Change from baseline after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | 6 |
| Vitamin E | -3 |
| Pioglitazone + Vitamin E | -16 |
Change from baseline after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | uU/ml (Mean) |
|---|---|
| Placebo | 3 |
| Vitamin E | -3 |
| Pioglitazone + Vitamin E | -3 |
Change from baseline in plasma HDL-cholesterol after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | -1 |
| Vitamin E | 1 |
| Pioglitazone + Vitamin E | 3 |
Change from baseline in plasma LDL-cholesterol after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | -12 |
| Vitamin E | 0 |
| Pioglitazone + Vitamin E | -4 |
Change from baseline in intrahepatic triglyceride content after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | percentage (Mean) |
|---|---|
| Placebo | 1 |
| Vitamin E | -6 |
| Pioglitazone + Vitamin E | -10 |
"Number of patients with reduction of at least 2 points in the nonalcoholic fatty liver disease activity score (NAS) (with reduction in at least 2 different histological categories) without worsening of fibrosis. NAS is the sum of the separate scores for steatosis (0-3), hepatocellular ballooning (0-2) and lobular inflammation (0-3), and ranges from 0-8 .~The scoring system is based on the following grading:~Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis." (NCT01002547)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 7 |
| Vitamin E | 13 |
| Pioglitazone + Vitamin E | 24 |
This is a method for assessing insulin resistance (IR) based on measurements of glucose and insulin during the oral glucose tolerance test. The formula used is = (10000/(SQRT(fasting plasma glucose * fasting plasma insulin * ((fasting plasma glucose * 15 + glucose at minute 30 * 30 + glucose at minute 60 * 30 + glucose at minute 90 * 30 + glucose at minute 120 * 15)/120)*((fasting plasma insulin * 15 + insulin at minute 30 * 30 + insulin at minute 60 * 30 + insulin at minute 90 * 30 + insulin at minute 120 * 15)/120))), with a lower value representing worse insulin resistance. (NCT01002547)
Timeframe: Month 18
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 2.53 |
| Vitamin E | 2.31 |
| Pioglitazone + Vitamin E | 4.02 |
Resolution of NASH was defined as absence of NASH after 18 months of therapy in patients with definite NASH (presence of zone 3 accentuation of macrovesicular steatosis of any grade, hepatocellular ballooning of any degree, and lobular inflammatory infiltrates of any amount) at baseline. (NCT01002547)
Timeframe: Month 18
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 5 |
| Vitamin E | 14 |
| Pioglitazone + Vitamin E | 20 |
Change from baseline in plasma ALT after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | U/L (Mean) |
|---|---|
| Placebo | -6 |
| Vitamin E | -24 |
| Pioglitazone + Vitamin E | -18 |
Change from baseline in plasma AST after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | U/L (Mean) |
|---|---|
| Placebo | -8 |
| Vitamin E | -15 |
| Pioglitazone + Vitamin E | -10 |
Change from baseline in total body fat by DEX after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | percentage (Mean) |
|---|---|
| Placebo | 0 |
| Vitamin E | 0 |
| Pioglitazone + Vitamin E | 2 |
Change from baseline in plasma total cholesterol after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | -11 |
| Vitamin E | 5 |
| Pioglitazone + Vitamin E | 1 |
Change from baseline in plasma triglycerides after 18 months of therapy (NCT01002547)
Timeframe: Month 18
| Intervention | mg/dl (Median) |
|---|---|
| Placebo | 13 |
| Vitamin E | 14 |
| Pioglitazone + Vitamin E | -2 |
Change from baseline in weight (NCT01002547)
Timeframe: Month 18
| Intervention | kg (Mean) |
|---|---|
| Placebo | -0.8 |
| Vitamin E | 0.5 |
| Pioglitazone + Vitamin E | 5.7 |
"Number of patients with improvement of at least 1 grade in each of the histological parameters.~Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x.~Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning.~Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis." (NCT01002547)
Timeframe: Month 18
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Steatosis | Inflammation | Ballooning | Fibrosis | |
| Pioglitazone + Vitamin E | 32 | 25 | 23 | 19 |
| Placebo | 15 | 14 | 11 | 10 |
| Vitamin E | 24 | 13 | 18 | 19 |
"Mean change in individual scores compared to baseline. Steatosis range 0-3, where: 0 = <5% fat; 1 = 5-33% fat; 2 = >33-66% fat; 3 = >66% fat.~Lobular Inflammation, range 0-3, where: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x.~Hepatocyte Ballooning, range 0-2, where: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning.~Fibrosis stage, range 0-4, where: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis." (NCT01002547)
Timeframe: Month 18
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Steatosis | Inflammation | Ballooning | Fibrosis | |
| Pioglitazone + Vitamin E | -1.3 | -0.6 | -0.6 | -0.6 |
| Placebo | -0.4 | -0.2 | -0.1 | -0.3 |
| Vitamin E | -1.0 | -0.4 | -0.5 | -0.6 |
High sensitivity C-reactive protein (range 0 - no maximum) (NCT01991197)
Timeframe: 16 weeks
| Intervention | µg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 8.4 |
The change in glucose from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks
| Intervention | mmol/L (Median) |
|---|---|
| Sitagliptin | -0.2 |
| Gliclazide | -0.1 |
The change in systolic blood pressure from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks
| Intervention | mmHg (Median) |
|---|---|
| Sitagliptin | 4 |
| Gliclazide | -9 |
The change in total cholesterol from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks
| Intervention | mmol/L (Median) |
|---|---|
| Sitagliptin | 0.1 |
| Gliclazide | -0.1 |
Psoriasis area and severity index 0-72, higher score worse outcome (NCT01991197)
Timeframe: baseline and 32 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Sitagliptin | 3 |
| Gliclazide | 1.8 |
Psoriasis area and severity index (0-72), higher scores worse outcome (NCT01991197)
Timeframe: 16 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Sitagliptin | 9.5 |
| Gliclazide | 9.4 |
The change in weight from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks
| Intervention | kg (Median) |
|---|---|
| Sitagliptin | -0.5 |
| Gliclazide | -0.6 |
Dipeptidyl peptidase-4 levels levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks
| Intervention | dCt (Median) |
|---|---|
| Gliclazide | -1.12 |
| Sitagliptin | 0 |
Interleukin 17 levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks
| Intervention | dCt (Median) |
|---|---|
| Sitagliptin | 3.41 |
| Gliclazide | 2.09 |
"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-17 (IL-17) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 0 |
"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-23 (IL-23) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 0 |
"Secondary outcomes:~The change in serum concentrations of the adipokine leptin Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | -0.07 |
| Gliclazide | 0.43 |
"Secondary outcomes:~The change in serum concentrations of the cytokines tumour necrosis factor alpha (TNFα) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 0 |
"Dosage: Sitagliptin: 100mg daily, or 50mg daily for participants with moderate kidney disease Gliclazide: 80-320 mg daily.~Secondary outcomes: the number participants with adverse events." (NCT01991197)
Timeframe: 32 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Sitagliptin | 6 |
| Gliclazide | 10 |
"Dermatology life quality index (a skin related quality of life measure) (0-10), higher score worse outcome EQ-5D Euroqol 5 item quality of life index comprising 5 dimensions mobility, self-care, usual activities, pain, anxiety. An index can be derived from these 5 dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state and minimum score indicating the worst health outcome -0.594.~HADS Hospital anxiety and depression scale 0-16 for anxiety and 0-16 for depression, higher score worse outcome HAQ-8 Stanford 8 item disability scale. Scoring is from 0 (without any difficulty) to 3 (unable to do). The 8 scores from the 8 sections are summed and divided by 8. The result is the disability index (range 0-3 with 25 possible values). A" (NCT01991197)
Timeframe: 16 weeks
| Intervention | score on a scale (Median) | ||||
|---|---|---|---|---|---|
| DLQI | HAQ-8 | HADS Anxiety | HADS Depression | EQ-5D | |
| Gliclazide | -1.0 | 0.0 | 0 | 0 | -0.2 |
| Sitagliptin | 0.0 | 0.0 | -1 | 0 | 0 |
"Secondary outcomes:~d. number or participants who acheived a greater than 50% reduction in PASI from baseline (PASI-50); e. number of participants who achieved PASI-75 and PASI-90." (NCT01991197)
Timeframe: 16 weeks
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| PASI 50 | PASI 75 | PASI 90 | |
| Gliclazide | 1 | 0 | 0 |
| Sitagliptin | 1 | 0 | 0 |
The change between Adiponectin collected at final visit or week 24 and Adiponectin collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | mcg/ml (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 7.8 |
| Pioglitazone 15 mg BID | 9.2 |
| Metformin 850 mg BID | -0.3 |
The change between the Fasting Insulin value collected at final visit or week 24 and Fasting Insulin collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | μIU/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -3.91 |
| Pioglitazone 15 mg BID | -3.18 |
| Metformin 850 mg BID | -0.98 |
The change between the value of Fasting Plasma Glucose collected at final visit or week 24 and Fasting Plasma Glucose collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -39.9 |
| Pioglitazone 15 mg BID | -22.2 |
| Metformin 850 mg BID | -24.8 |
The change between High-Density Lipoprotein Cholesterol collected at final visit or week 24 and High-Density Lipoprotein Cholesterol collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 14.20 |
| Pioglitazone 15 mg BID | 9.88 |
| Metformin 850 mg BID | 6.09 |
The change between Homeostasis Model Assessment of Insulin Resistance collected at final visit or week 24 and Homeostasis Model Assessment of Insulin Resistance collected at baseline. Homeostasis Model Assessment measures insulin resistance, calculated by insulin times glucose, divided by a constant (22.5). (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | percent of insulin resistance (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -2.704 |
| Pioglitazone 15 mg BID | -2.075 |
| Metformin 850 mg BID | -1.085 |
The change between Intermediate-Density Low Density Lipoprotein collected at final visit or week 24 and Intermediate-Density Low Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -16.3 |
| Pioglitazone 15 mg BID | -11.0 |
| Metformin 850 mg BID | -17.3 |
The change between Intermediate-Medium High Density Lipoprotein collected at final visit or week 24 and Intermediate-Medium High Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | μmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 1.34 |
| Pioglitazone 15 mg BID | 1.62 |
| Metformin 850 mg BID | -0.09 |
The change between Large High Density Lipoprotein collected at final visit or week 24 and Large High Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | μmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 0.70 |
| Pioglitazone 15 mg BID | 1.02 |
| Metformin 850 mg BID | 0.52 |
The change between Large Low Density Lipoprotein collected at final visit or week 24 and Large Low Density Lipoprotein collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 96.0 |
| Pioglitazone 15 mg BID | 115.7 |
| Metformin 850 mg BID | 18.4 |
The change between Large-Chylomicrons Very Low Density Lipoprotein collected at final visit or week 24 and Large-Chylomicrons Very Low Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -1.71 |
| Pioglitazone 15 mg BID | -1.97 |
| Metformin 850 mg BID | -1.96 |
The change between Low-Density Lipoprotein Cholesterol collected at final visit or week 24 and Low-Density Lipoprotein Cholesterol collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 1.19 |
| Pioglitazone 15 mg BID | 6.08 |
| Metformin 850 mg BID | -1.37 |
The change between High Density Lipoprotein collected at final visit or week 24 and High Density Lipoprotein collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | μmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 0.28 |
| Pioglitazone 15 mg BID | -0.80 |
| Metformin 850 mg BID | 0.62 |
The change between High Density Lipoprotein collected at final visit or week 24 and High Density Lipoprotein collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nm (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 0.15 |
| Pioglitazone 15 mg BID | 0.19 |
| Metformin 850 mg BID | 0.11 |
The change between Low Density Lipoprotein particle concentration collected at final visit or week 24 and Low Density Lipoprotein particle concentration collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -240.6 |
| Pioglitazone 15 mg BID | -217.2 |
| Metformin 850 mg BID | -176.4 |
The change between Low Density Lipoprotein collected at final visit or week 24 and Low Density Lipoprotein collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nm (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 0.55 |
| Pioglitazone 15 mg BID | 0.6 |
| Metformin 850 mg BID | 0.2 |
The change between Very Low Density Lipoprotein collected at final visit or week 24 and Very Low Density Lipoprotein collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -2.78 |
| Pioglitazone 15 mg BID | 0.98 |
| Metformin 850 mg BID | -11.30 |
The change between Very Low Density Lipoprotein collected at final visit or week 24 and Very Low Density Lipoprotein collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nm (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -2.64 |
| Pioglitazone 15 mg BID | -3.79 |
| Metformin 850 mg BID | -0.20 |
The change between Medium-Intermediate Very Low Density Lipoprotein collected at final visit or week 24 and Medium-Intermediate Very Low Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -4.07 |
| Pioglitazone 15 mg BID | -3.01 |
| Metformin 850 mg BID | -6.48 |
The change between Medium-Small Low Density Lipoprotein collected at final visit or week 24 and Medium-Small Low Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -63.8 |
| Pioglitazone 15 mg BID | -66.0 |
| Metformin 850 mg BID | -35.3 |
The change between Small High Density Lipoprotein collected at final visit or week 24 and Small High Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | μmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -1.78 |
| Pioglitazone 15 mg BID | -3.41 |
| Metformin 850 mg BID | 0.19 |
The change between Small Low Density Lipoprotein collected at final visit or week 24 and Small Low Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -319.3 |
| Pioglitazone 15 mg BID | -321.3 |
| Metformin 850 mg BID | -179.0 |
The change between Small Very Low Density Lipoprotein collected at final visit or week 24 and Small Very Low Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 3.05 |
| Pioglitazone 15 mg BID | 5.9 |
| Metformin 850 mg BID | -2.86 |
The change between Total Cholesterol collected at final visit or week 24 and Total Cholesterol collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | 1.06 |
| Pioglitazone 15 mg BID | 4.79 |
| Metformin 850 mg BID | -2.72 |
The change between Triglycerides collected at final visit or week 24 and Triglycerides collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -5.95 |
| Pioglitazone 15 mg BID | -5.54 |
| Metformin 850 mg BID | -1.78 |
The change between Very Small Low Density Lipoprotein collected at final visit or week 24 and Very Small Low Density Lipoprotein collected at baseline (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -255.5 |
| Pioglitazone 15 mg BID | -255.2 |
| Metformin 850 mg BID | -143.8 |
Measurement for High Sensitivity C-reactive Protein was collected at final visit or week 24 and at baseline. Percent change from baseline is calculated as: [(Week 24 - baseline levels)/baseline]*100 (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | percent (Median) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -36.7 |
| Pioglitazone 15 mg BID | -34.0 |
| Metformin 850 mg BID | -26.2 |
The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final visit or week 24 and Glycosylated Hemoglobin collected at baseline. (NCT00727857)
Timeframe: Baseline and Week 24
| Intervention | percentage of Glycosylated Hemoglobin (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | -1.83 |
| Pioglitazone 15 mg BID | -0.96 |
| Metformin 850 mg BID | -0.99 |
Fraction Exhaled Nitric oxide was measured on each visit prior to bronchoprovocation by chemiluminescence using an analyzer. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | parts per billion (Mean) | |
|---|---|---|
| Baseline | 12 weeks | |
| Rosiglitazone | 48 | 41 |
FEV1 in liters (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | Liters (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 2.95 | 3.04 |
Spirometry was performed on each visit according to American Thoracic Society guidelines. FEV1 percent predicted was measured. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | percent predicted (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 82 | 85 |
PC20 is the concentration of methacholine at which patients had a decrease in Forced Expiratory Volume in one second (FEV1) of 20% (NCT00614874)
Timeframe: patients were assessed at baseline and at 12 weeks
| Intervention | mg/mL (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 3.27 | 8.71 |
19 reviews available for pioglitazone and Innate Inflammatory Response
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease.
Topics: Adipose Tissue; Chronic Disease; COVID-19; Diabetes Mellitus, Type 2; Humans; Inflammation; Insulin; | 2022 |
A Scoping Review of the Use of Pioglitazone in the Treatment of Temporo-Mandibular Joint Arthritis.
Topics: Animals; Arthritis, Rheumatoid; Inflammation; Pioglitazone; Temporomandibular Joint; Temporomandibul | 2022 |
Can pioglitazone be used for optimization of nutrition in critical illness? A systematic review.
Topics: Adult; Critical Illness; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Pioglitazone | 2023 |
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Topics: Chalcones; Diabetes Mellitus, Type 2; Drug Development; Fatty Liver; Humans; Hypoglycemic Agents; In | 2019 |
Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?
Topics: Anti-Inflammatory Agents; Comorbidity; COVID-19; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV | 2020 |
Diabetes, stroke, and neuroresilience: looking beyond hyperglycemia.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Inflammation; Insulin; Insuli | 2021 |
Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
Topics: Gastrointestinal Microbiome; Humans; Hypoglycemic Agents; Inflammation; Liver Cirrhosis; Liver Neopl | 2017 |
Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials.
Topics: Adult; Antidepressive Agents; Blood Glucose; Clinical Trials as Topic; Depression; Diabetes Mellitus | 2018 |
Nonalcoholic Fatty Liver Disease and Obesity Treatment.
Topics: Bariatric Surgery; Body Weight; Diet; Exercise; Glucagon-Like Peptide 1; Humans; Inflammation; Insul | 2019 |
Treatment of non-alcoholic fatty liver disease.
Topics: Animals; Fatty Liver; Humans; Inflammation; Insulin Resistance; Life Style; Liver Transplantation; M | 2013 |
Modulatory effects of peroxisome proliferator-activated receptor-γ on CXCR3 chemokines.
Topics: Animals; Autoimmune Diseases; Chemokines; Disease Models, Animal; Europe; Humans; Immunity, Cellular | 2014 |
The blood-brain barrier as a target in traumatic brain injury treatment.
Topics: Blood-Brain Barrier; Brain Edema; Brain Injuries; Cell Hypoxia; Humans; Hypoglycemic Agents; Inflamm | 2014 |
Pioglitazone and mechanisms of CV protection.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angi | 2010 |
High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone.
Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus; Humans; | 2010 |
[Prevention, treatment and management of inflammation in atherosclerosis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Biomarkers; C-Reactive Protein; Chronic D | 2011 |
The Clinical Significance of PPAR Gamma Agonism.
Topics: Animals; Blood Glucose; Blood Pressure; Cardiovascular System; Coagulants; Cytokines; Diabetes Melli | 2005 |
Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Topics: Atherosclerosis; Blood Platelets; Coronary Disease; Diabetic Angiopathies; Endothelium, Vascular; Hu | 2006 |
[Microinflammation in the pathogenesis of diabetic nephropathy].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Diabetic Nephropathies; | 2007 |
23 trials available for pioglitazone and Innate Inflammatory Response
| Article | Year |
|---|---|
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; P | 2023 |
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; P | 2023 |
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; P | 2023 |
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; P | 2023 |
Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
Topics: Adult; Biomarkers; Biopsy; Female; Humans; Hypoglycemic Agents; Inflammation; Liver; Liver Cirrhosis | 2020 |
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Topics: Adult; Biopsy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Hu | 2019 |
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Topics: Adult; Biopsy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Hu | 2019 |
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Topics: Adult; Biopsy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Hu | 2019 |
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Topics: Adult; Biopsy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Hu | 2019 |
Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
Topics: Adult; Biomarkers; Chemokines; Cytokines; Drug Therapy, Combination; Female; Glucose Clamp Technique | 2013 |
Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis.
Topics: Aged; alpha-2-HS-Glycoprotein; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Fenofibrate; H | 2015 |
Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Biomarkers; Deoxyguanosine; Disease Progression; Female; Gene Exp | 2015 |
[Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease].
Topics: Asthma; Cardiovascular Agents; Coronary Disease; Drug Monitoring; Drug Therapy, Combination; Endothe | 2015 |
The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
Topics: Animals; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelins; Female; Humans; Hypoglycemic A | 2008 |
Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Calibration; Carotid Stenosis; Diabetes Complications; Diabetes Melli | 2009 |
Effect of pioglitazone on systemic inflammation is independent of metabolic control and cardiac autonomic function in patients with type 2 diabetes.
Topics: Aged; C-Reactive Protein; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Heart; Heart Rate; Hu | 2010 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double | 2010 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double | 2010 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double | 2010 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2010 |
Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
Topics: Acarbose; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Fem | 2010 |
Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes.
Topics: Adiponectin; Adult; Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus | 2010 |
The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study.
Topics: Aged; Biomarkers; Blood Coagulation; Blood Platelets; Body Mass Index; Diabetes Mellitus, Type 2; Fe | 2011 |
Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Blood Vessels; Cardiovascular Diseases; Diabetes C | 2011 |
Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
Topics: Aged; Anti-Inflammatory Agents; Aortic Diseases; Aortography; Biomarkers; Blood Glucose; C-Reactive | 2011 |
Comparable effects of pioglitazone and perindopril on circulating endothelial progenitor cells, inflammatory process and oxidative stress in patients with diabetes mellitus.
Topics: Aged; Diabetes Mellitus; Endothelial Cells; Female; Hematopoietic Stem Cells; Humans; Inflammation; | 2012 |
Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients.
Topics: Apelin; Blood Glucose; Body Mass Index; Chemokines; Diabetes Mellitus, Type 2; Dinoprost; Humans; Hy | 2012 |
Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cell Adhesion Molecules; Diabetes Mel | 2013 |
Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Coronary Disease; C | 2005 |
Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men.
Topics: Adult; Arteries; Blood Pressure; Cell Adhesion Molecules; Cytokines; Double-Blind Method; Elasticity | 2007 |
Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.
Topics: Antihypertensive Agents; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ang | 2008 |
136 other studies available for pioglitazone and Innate Inflammatory Response
| Article | Year |
|---|---|
Vitamin D Combined with Pioglitazone Mitigates Type-2 Diabetes-induced Hepatic Injury Through Targeting Inflammation, Apoptosis, and Oxidative Stress.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Biomarkers; Diabetes Mellitus, Experimental; Diabetes | 2022 |
Pioglitazone Ameliorates Acute Endotoxemia-Induced Acute on Chronic Renal Dysfunction in Cirrhotic Ascitic Rats.
Topics: Acute Disease; Alanine Transaminase; Animals; Ascites; Bile Ducts; Bilirubin; Blood Vessels; Chronic | 2021 |
PPARγ regulates the expression of genes involved in the DNA damage response in an inflamed endometrium.
Topics: Animals; DNA Damage; Endometrium; Female; Inflammation; Ligands; Lipopolysaccharides; Pioglitazone; | 2022 |
Therapeutic potential of deuterium-stabilized (R)-pioglitazone-PXL065-for X-linked adrenoleukodystrophy.
Topics: Adrenoleukodystrophy; Animals; ATP Binding Cassette Transporter, Subfamily D, Member 1; ATP-Binding | 2022 |
The PPAR-γ agonist pioglitazone exerts proinflammatory effects in bronchial epithelial cells during acute Pseudomonas aeruginosa pneumonia.
Topics: Animals; Epithelial Cells; Hypoglycemic Agents; Inflammation; Mice; Pioglitazone; Pneumonia; PPAR ga | 2022 |
Luteolin alleviates inflammation and autophagy of hippocampus induced by cerebral ischemia/reperfusion by activating PPAR gamma in rats.
Topics: Animals; Autophagy; Brain Ischemia; Hippocampus; Inflammation; Luteolin; Molecular Docking Simulatio | 2022 |
PPAR-γ alleviates the inflammatory response in TNF-α-induced fibroblast-like synoviocytes by binding to p53 in rheumatoid arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Cell Proliferation; Cells, Cultured; Fibrob | 2023 |
Pioglitazone attenuates ischaemic stroke aggravation by blocking PPARγ reduction and inhibiting chronic inflammation in diabetic mice.
Topics: Animals; Brain Ischemia; Diabetes Mellitus, Experimental; Inflammation; Ischemic Stroke; Mice; NLR F | 2022 |
Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compounds; Biomarkers; Cholesterol; Chol | 2022 |
Single-cell transcriptomics reveal cellular diversity of aortic valve and the immunomodulation by PPARγ during hyperlipidemia.
Topics: Animals; Aortic Valve; Aortic Valve Stenosis; Calcinosis; Cells, Cultured; Endothelial Cells; Humans | 2022 |
Pioglitazone Attenuates the Effects of Peripheral Inflammation in a Human In Vitro Blood-Brain Barrier Model.
Topics: Blood-Brain Barrier; Claudin-5; Humans; Inflammation; Inflammatory Bowel Diseases; Intercellular Adh | 2022 |
A novel approach to repositioning memantine for metabolic syndrome-induced steatohepatitis: Modulation of hepatic autophagy, inflammation, and fibrosis.
Topics: Animals; Autophagy; Fatty Liver; Fibrosis; Inflammation; Lipids; Liver; Male; Memantine; Metabolic S | 2023 |
Pioglitazone inhibits oxidative stress, MMP-mediated inflammation and vascular dysfunction in high glucose-induced human saphenous vein grafts.
Topics: Glucose; Humans; Inflammation; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Matrix Metal | 2023 |
Paraquat-induced systemic inflammation and oxidative stress in rats improved by Curcuma longa ethanolic extract, curcumin and a PPAR agonist.
Topics: Animals; Curcuma; Curcumin; Hypoglycemic Agents; Inflammation; Oxidative Stress; Paraquat; Pioglitaz | 2023 |
Pioglitazone ameliorates cisplatin-induced testicular toxicity by attenuating oxidative stress and inflammation via TLR4/MyD88/NF-κB signaling pathway.
Topics: Animals; Cisplatin; Inflammation; Myeloid Differentiation Factor 88; NF-kappa B; Oxidative Stress; P | 2023 |
PPARG stimulation restored lung mRNA expression of core clock, inflammation- and metabolism-related genes disrupted by reversed feeding in male mice.
Topics: Animals; Dimercaprol; Inflammation; Interleukin-6; Lung; Male; Mice; Pioglitazone; PPAR gamma; RNA, | 2023 |
Pioglitazone ameliorates DOX-induced cognitive impairment by mitigating inflammation, oxidative stress, and apoptosis of hippocampal neurons in rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Chemotherapy-Related Cognitive Impairment | 2024 |
Adding SGLT2 Cotransporter Inhibitor to PPARγ Activator Does Not Provide an Additive Effect in the Management of Diabetes-Induced Vascular Dysfunction.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Infl | 2023 |
Pioglitazone attenuates tamoxifen-induced liver damage in rats via modulating Keap1/Nrf2/HO-1 and SIRT1/Notch1 signaling pathways: In-vivo investigations, and molecular docking analysis.
Topics: Animals; Antioxidants; Chemical and Drug Induced Liver Injury; Inflammation; Kelch-Like ECH-Associat | 2023 |
Amelioration of perivascular adipose inflammation reverses vascular dysfunction in a model of nonobese prediabetic metabolic challenge: potential role of antidiabetic drugs.
Topics: Adipose Tissue; Animals; Disease Models, Animal; Feeding Behavior; Hypoglycemic Agents; Inflammation | 2019 |
An apoptotic body-biomimic liposome in situ upregulates anti-inflammatory macrophages for stabilization of atherosclerotic plaques.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Biomimetic Materials; Cytokin | 2019 |
Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: Targeting Nav1.7 channels and PPAR-γ.
Topics: Animals; Behavior, Animal; Comorbidity; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet | 2020 |
Maternal high fructose-induced hippocampal neuroinflammation in the adult female offspring via PPARγ-NF-κB signaling.
Topics: Animals; Cytokines; Diet; Female; Fructose; Hippocampus; Inflammation; Inflammation Mediators; Male; | 2020 |
Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?
Topics: Anti-Inflammatory Agents; Betacoronavirus; C-Reactive Protein; Coronavirus Infections; COVID-19; COV | 2020 |
PPARγ-mediated microglial activation phenotype is involved in depressive-like behaviors and neuroinflammation in stressed C57BL/6J and ob/ob mice.
Topics: Animals; Behavior, Animal; Cognitive Dysfunction; Cytokines; Depression; Disease Models, Animal; Hip | 2020 |
Worsening baroreflex sensitivity on progression to type 2 diabetes: localized vs. systemic inflammation and role of antidiabetic therapy.
Topics: Animals; Baroreflex; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dia | 2020 |
Transcriptome analysis of porcine endometrium after LPS-induced inflammation: effects of the PPAR-gamma ligands in vitro†.
Topics: Alternative Splicing; Animals; Benzamides; Endometrium; Female; Gene Expression Profiling; Inflammat | 2021 |
Ischemia reperfusion-induced metastasis is resistant to PPARγ agonist pioglitazone in a murine model of colon cancer.
Topics: Animals; Colonic Neoplasms; Cytokines; Disease Models, Animal; Disease Progression; Inflammation; Li | 2020 |
Rice Bran Extract Protected against LPS-Induced Neuroinflammation in Mice through Targeting PPAR-γ Nuclear Receptor.
Topics: Anilides; Animals; Brain; Cyclooxygenase 2; Esters; Fatty Acids; Gene Expression Regulation; Inflamm | 2021 |
Phloroglucinol prevents albumin glycation as well as diminishes ROS production, glycooxidative damage, nitrosative stress and inflammation in hepatocytes treated with high glucose.
Topics: Albumins; Antioxidants; Ascorbic Acid; Glucose; Glycation End Products, Advanced; Guanidines; Hep G2 | 2021 |
Post-treatment with the PPAR-γ agonist pioglitazone inhibits inflammation and bacterial growth during Klebsiella pneumonia.
Topics: Animals; Female; Inflammation; Injections, Intraperitoneal; Klebsiella Infections; Klebsiella pneumo | 2021 |
Immunomodulation in systemic lupus erythematosus: induction of M2 population in monocyte-derived macrophages by pioglitazone.
Topics: Adolescent; Adult; Case-Control Studies; Cytokines; Female; Humans; Immunomodulation; Inflammation; | 2017 |
Ameliorating the Effect of Pioglitazone on LPS-Induced Inflammation of Human Oligodendrocyte Progenitor Cells.
Topics: Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Embryonic Stem Cells; Humans; Hypoglyc | 2018 |
Docosahexaenoic acid promotes oligodendrocyte differentiation via PPAR-γ signalling and prevents tumor necrosis factor-α-dependent maturational arrest.
Topics: Animals; Cell Differentiation; Cells, Cultured; Demyelinating Diseases; Docosahexaenoic Acids; Fatty | 2017 |
Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study.
Topics: Animals; Biomarkers; Biopsy; Fibrosis; Gene Expression; Inflammation; Lipid Metabolism; Male; Mice; | 2017 |
Effect of pioglitazone on inflammation and calcification in atherosclerotic rabbits : An
Topics: Animals; Atherosclerosis; Calcinosis; Fluorodeoxyglucose F18; Hypoglycemic Agents; Inflammation; Mal | 2018 |
Human Skin Permeation Studies with PPARγ Agonist to Improve Its Permeability and Efficacy in Inflammatory Processes.
Topics: Adult; Cell Line; Chromatography, High Pressure Liquid; Cyclohexenes; Female; Humans; Hypoglycemic A | 2017 |
Inflammatory Response Modulation through a PPARγ Agonist during Surgically Induced Visceral Ischemia in an Animal Model.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Constriction; Cytoprotection; Disease Models, Animal; Infl | 2018 |
Pioglitazone Inhibits Periprostatic White Adipose Tissue Inflammation in Obese Mice.
Topics: Adipose Tissue, White; Animals; Cells, Cultured; Chemokine CCL2; Diet, High-Fat; Hypoglycemic Agents | 2018 |
Acute loss of adipose tissue-derived adiponectin triggers immediate metabolic deterioration in mice.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Animals; Blood Glucose; Gene Deletion; Gene Expression Prof | 2018 |
Modulation of lipid mediator profile may contribute to amelioration of chronic inflammation in adipose tissue of obese mice by pioglitazone.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Chronic Disease; Cytokines; Diabetes Mellitus, Ty | 2018 |
Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: Involvement of CB2 and PPAR-γ receptors.
Topics: Animals; Diet; Dyslipidemias; Inflammation; Male; Pioglitazone; Polycyclic Sesquiterpenes; PPAR alph | 2019 |
Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Cholesterol; Diet, High-F | 2019 |
Pioglitazone prevents sevoflurane‑induced neuroinflammation and cognitive decline in a rat model of chronic intermittent hypoxia by upregulating hippocampal PPAR‑γ.
Topics: Animals; Chronic Disease; Cognitive Dysfunction; Disease Models, Animal; Hippocampus; Hypoglycemic A | 2019 |
Nanoemulsion strategy of pioglitazone for the treatment of skin inflammatory diseases.
Topics: Adult; Animals; Anti-Inflammatory Agents; Cytokines; Drug Liberation; Emulsions; Female; Humans; Inf | 2019 |
Dietary fructose-induced gut dysbiosis promotes mouse hippocampal neuroinflammation: a benefit of short-chain fatty acids.
Topics: Animals; Doublecortin Protein; Dysbiosis; Fatty Acids, Volatile; Fructose; Gastrointestinal Microbio | 2019 |
A selective peroxisome proliferator-activated receptor-γ agonist benefited propionic acid induced autism-like behavioral phenotypes in rats by attenuation of neuroinflammation and oxidative stress.
Topics: Animals; Anxiety; Autism Spectrum Disorder; Behavior, Animal; Brain; Disease Models, Animal; Explora | 2019 |
The Function of PPARγ/AMPK/SIRT-1 Pathway in Inflammatory Response of Human Articular Chondrocytes Stimulated by Advanced Glycation End Products.
Topics: AMP-Activated Protein Kinases; Cartilage, Articular; Cells, Cultured; Chondrocytes; Glycation End Pr | 2019 |
The effect of peroxisome proliferator-activated receptor-γ ligands on in vitro and in vivo models of COPD.
Topics: Adrenal Cortex Hormones; Aged; Animals; Apoptosis; Chemokine CCL5; Dexamethasone; Female; Gene Expre | 2014 |
A peroxisome proliferator-activated receptor gamma agonist attenuates neurological deficits following spinal cord ischemia in rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Disease Models, Animal; Infarction; Inflammation; M | 2014 |
Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis.
Topics: Adipokines; Animals; Cytokines; Hypoglycemia; Hypoglycemic Agents; I-kappa B Proteins; Inflammation; | 2014 |
Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pr | 2013 |
Anti-arthritic and anti-inflammatory activity of combined pioglitazone and prednisolone on adjuvant-induced arthritis.
Topics: Animals; Ankle; Anti-Inflammatory Agents; Arthritis, Experimental; Body Weight; Disease Progression; | 2013 |
An ophthalmic solution of a peroxisome proliferator-activated receptor gamma agonist prevents corneal inflammation in a rat alkali burn model.
Topics: Alkalies; Animals; Burns, Chemical; Chemokines; Collagen Type III; Cornea; Corneal Neovascularizatio | 2013 |
Regulation of diet-induced adipose tissue and systemic inflammation by salicylates and pioglitazone.
Topics: Adipose Tissue; Animals; Cell Count; Diet, High-Fat; Flow Cytometry; Gene Expression Profiling; Gene | 2013 |
Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats.
Topics: Animals; Cell Movement; Disease Models, Animal; Hemodynamics; Human Umbilical Vein Endothelial Cells | 2014 |
PPARγ and RXR ligands disrupt the inflammatory cross-talk in the hypoxic breast cancer stem cells niche.
Topics: Antigens, Neoplasm; Apolipoproteins E; Biomarkers, Tumor; Breast Neoplasms; Carbonic Anhydrase IX; C | 2014 |
Atherogenic mononuclear cell recruitment is facilitated by oxidized lipoprotein-induced endothelial junctional adhesion molecule-A redistribution.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Cell Adhesion Molecules; Cell | 2014 |
Pioglitazone treatment reduces adipose tissue inflammation through reduction of mast cell and macrophage number and by improving vascularity.
Topics: Adipocytes; Adipose Tissue; Adult; Elastin; Female; Fish Oils; Humans; Inflammation; Insulin Resista | 2014 |
PPARγ is involved in the hyperglycemia-induced inflammatory responses and collagen degradation in human chondrocytes and diabetic mouse cartilages.
Topics: Adult; Aged; Animals; Cartilage; Chondrocytes; Collagen; Diabetes Mellitus, Experimental; Dinoprosto | 2015 |
The effect of PPAR-γ agonist on (18)F-FDG PET imaging for differentiating tumors and inflammation lesions.
Topics: Anilides; Animals; Biological Transport; Cell Line, Tumor; Diagnosis, Differential; Female; Fluorode | 2015 |
Geraniol, alone and in combination with pioglitazone, ameliorates fructose-induced metabolic syndrome in rats via the modulation of both inflammatory and oxidative stress status.
Topics: Acyclic Monoterpenes; Adiponectin; Adipose Tissue; Adiposity; Animals; Blood Pressure; Body Weight; | 2015 |
Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
Topics: Amino Acids; Animals; Choline Deficiency; Food, Formulated; Glucosides; Hydroxyproline; Hypoglycemic | 2015 |
Plaque Thrombosis is Reduced by Attenuating Plaque Inflammation with Pioglitazone and is Evaluated by Fluorodeoxyglucose Positron Emission Tomography.
Topics: Animals; Biomarkers; Blood Glucose; C-Reactive Protein; Fluorodeoxyglucose F18; Hypoglycemic Agents; | 2015 |
LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).
Topics: Animals; Cyclooxygenase 2; Diet, High-Fat; Disease Models, Animal; Epidermal Growth Factor; I-kappa | 2015 |
The Role of PPARγ in Advanced Glycation End Products-Induced Inflammatory Response in Human Chondrocytes.
Topics: Adult; Cartilage, Articular; Cells, Cultured; Chondrocytes; Female; Glycation End Products, Advanced | 2015 |
Pioglitazone in adult rats reverses immediate postnatal overfeeding-induced metabolic, hormonal, and inflammatory alterations.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adiponectin; Adipose Tissue; Animals; Drug Evaluation, | 2015 |
Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Apolipoproteins E; Apoptosis; Atheroscle | 2015 |
Hyperglycemia and PPARγ Antagonistically Influence Macrophage Polarization and Infarct Healing After Ischemic Stroke.
Topics: Animals; Anticoagulants; Cell Polarity; Cerebral Hemorrhage; Diabetes Mellitus, Experimental; Diseas | 2015 |
Protective effect of pioglitazone on morphine-induced neuroinflammation in the rat lumbar spinal cord.
Topics: Animals; Cytokines; Drug Tolerance; Inflammation; Lumbar Vertebrae; Male; Morphine; Pioglitazone; PP | 2015 |
MicroRNA-223 is a crucial mediator of PPARγ-regulated alternative macrophage activation.
Topics: 3' Untranslated Regions; Adipocytes; Animals; Bone Marrow; Chromatin Immunoprecipitation; Diet, High | 2015 |
TLR4‑dependent signaling pathway modulation: A novel mechanism by which pioglitazone protects against nutritional fibrotic steatohepatitis in mice.
Topics: Animals; Chemokines; Choline; Diet; Down-Regulation; Fibrosis; Inflammation; Liver; Liver Cirrhosis; | 2016 |
Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Inflammation; Mese | 2016 |
Pioglitazone alleviates inflammation in diabetic mice fed a high-fat diet via inhibiting advanced glycation end-product-induced classical macrophage activation.
Topics: Animals; Anti-Inflammatory Agents; Bone Marrow; Diabetes Mellitus, Experimental; Diet, High-Fat; Gly | 2016 |
Pioglitazone inhibits growth of human retinoblastoma cells via regulation of NF-κB inflammation signals.
Topics: Animals; Apoptosis; Blotting, Western; Cell Proliferation; Gene Expression Regulation, Neoplastic; H | 2017 |
Pioglitazone Attenuates Neuroinflammation and Promotes Dopaminergic Neuronal Survival in the Nigrostriatal System of Rats after Diffuse Brain Injury.
Topics: Animals; Brain Injuries, Diffuse; Cell Survival; Dopaminergic Neurons; Inflammation; Inflammation Me | 2017 |
Potentiation of indomethacin-induced anti-inflammatory response by pioglitazone in carrageenan-induced acute inflammation in rats: Role of PPARγ receptors.
Topics: Animals; Anti-Inflammatory Agents; Carrageenan; Cyclooxygenase Inhibitors; Dinoprostone; Drug Synerg | 2016 |
Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats.
Topics: Adamantane; Animals; Blood Glucose; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2016 |
Effect of pioglitazone on metabolic features in endotoxemia model in obese diabetic db/db mice.
Topics: Adipogenesis; Adipose Tissue, White; Animals; Blood Glucose; Diabetes Mellitus; Endotoxemia; Female; | 2017 |
Peroxisome proliferator-activated receptor-γ agonist pioglitazone reduces the development of necrotizing enterocolitis in a neonatal preterm rat model.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Enterocoliti | 2017 |
Pharmacological differences of glitazones: does peroxisome proliferator-activated receptor-alpha activation make the difference?
Topics: Diabetes Mellitus, Type 2; Endothelins; Humans; Inflammation; Pioglitazone; PPAR alpha; PPAR gamma; | 2008 |
Prevention of steatohepatitis by pioglitazone: implication of adiponectin-dependent inhibition of SREBP-1c and inflammation.
Topics: Adiponectin; AMP-Activated Protein Kinase Kinases; Animals; Choline Deficiency; DNA Primers; Fatty L | 2009 |
Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus.
Topics: Animals; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Fibrosis; Glomerulosclerosis, Focal | 2009 |
Adipose tissue collagen VI in obesity.
Topics: Adipocytes; Adipose Tissue; Adolescent; Adult; Antigens, CD; Antigens, Differentiation, Myelomonocyt | 2009 |
Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study.
Topics: Adult; Aged; Blood Glucose; C-Reactive Protein; Cholesterol, LDL; Enzyme-Linked Immunosorbent Assay; | 2009 |
Pioglitazone suppresses the lipopolysaccharide-induced production of inflammatory factors in mouse macrophages by inactivating NF-kappaB.
Topics: Animals; Cell Line; Group V Phospholipases A2; Group X Phospholipases A2; Humans; Hypoglycemic Agent | 2010 |
Effects of long-term pioglitazone treatment on peripheral and central markers of aging.
Topics: Aging; Alzheimer Disease; Animals; Biomarkers; Brain; Hippocampus; Hypoglycemic Agents; Inflammation | 2010 |
PPARγ agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways.
Topics: Animals; Cell Line; Cytokines; Hypoglycemic Agents; Inflammation; Interleukin-1beta; Interleukin-6; | 2010 |
Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipoproteins E; Carotid Artery Diseases; Choles | 2010 |
PPARγ activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease.
Topics: Animals; Cytokines; Gene Deletion; Gene Expression Regulation; Granulomatous Disease, Chronic; Human | 2010 |
Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats.
Topics: Administration, Oral; Animals; Atrial Fibrillation; Blotting, Western; Disease Models, Animal; Echoc | 2011 |
Inflammatory responses in the atria: should they stay or should they go?
Topics: Animals; Atrial Fibrillation; Disease Models, Animal; Fibrosis; Heart Atria; Inflammation; Inflammat | 2011 |
Effects of two oral antidiabetics, pioglitazone and repaglinide, on aconitase inactivation, inflammation and oxidative/nitrosative stress in tissues under alloxan-induced hyperglycemia.
Topics: Aconitate Hydratase; Administration, Oral; Alloxan; Animals; Blood Glucose; Body Weight; Carbamates; | 2011 |
Candesartan with pioglitazone protects against endothelial dysfunction and inflammatory responses in porcine coronary arteries implanted with sirolimus-eluting stents.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2011 |
Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts.
Topics: Cell Adhesion; Cells, Cultured; Fibroblasts; Fibrosis; Glucuronosyltransferase; Humans; Hyaluronan S | 2011 |
The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.
Topics: Animals; Behavior, Animal; Brain; Corpus Striatum; Dopamine; Female; Hypoglycemic Agents; Inflammati | 2011 |
Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortography; Atherosclerosis; Biomarkers; Contrast Media; | 2011 |
Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Aortography; Atherosclerosis; Carotid Art | 2011 |
Imaging of pharmacologic intervention decoding therapeutic mechanism or defining effectiveness?
Topics: Anti-Inflammatory Agents; Aortic Diseases; Aortography; Carotid Artery Diseases; Diabetes Mellitus, | 2011 |
Peroxisome proliferator-activated receptor-γ regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure.
Topics: Animals; Body Weight; Cytokines; Eating; Heart Failure; Inflammation; Male; Models, Animal; NF-kappa | 2012 |
Effects of the insulin sensitizing drug, pioglitazone, and lipopolysaccharide administration on markers of systemic inflammation and clinical parameters in horses.
Topics: Adipose Tissue; Animals; Biomarkers; Chemokine CCL2; Chemokine CCL8; Female; Horse Diseases; Horses; | 2012 |
Potential role of insulin signaling on vascular smooth muscle cell migration, proliferation, and inflammation pathways.
Topics: Cell Communication; Cell Movement; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, | 2012 |
Three-month treatment with pioglitazone reduces circulating levels of S100A8/A9 (MRP8/14) complex, a biomarker of inflammation, without changes in body mass index, in type 2 diabetics with abdominal obesity.
Topics: Aged; Biomarkers; Body Mass Index; Calgranulin A; Calgranulin B; Diabetes Mellitus, Type 2; Female; | 2012 |
2-hydroxy-4'-methoxychalcone inhibits proliferation and inflammation of human aortic smooth muscle cells by increasing the expression of peroxisome proliferator-activated receptor gamma.
Topics: Aorta; Atherosclerosis; Cell Cycle; Cell Proliferation; Chalcones; Drug Synergism; Gene Expression R | 2012 |
Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Humans; Inflammation; Interleukin-6; Neop | 2012 |
PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells.
Topics: Adipose Tissue; Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Epididymis; Forkhead Trans | 2012 |
Pioglitazone, a peroxisome proliferator activated receptor γ agonist, decreases renal crystal deposition, oxidative stress and inflammation in hyperoxaluric rats.
Topics: Animals; Crystallization; Hyperoxaluria; Inflammation; Kidney; Kidney Calculi; Male; Oxidative Stres | 2012 |
Type I interferons promote fatal immunopathology by regulating inflammatory monocytes and neutrophils during Candida infections.
Topics: Animals; Antigens, CD; Antigens, Ly; Candida albicans; Candidemia; Candidiasis; Chemokine CCL2; Chem | 2012 |
The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.
Topics: Adult; Alanine Transaminase; Blood Glucose; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Dru | 2012 |
Antiinflammatory and antiarteriosclerotic effects of pioglitazone.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Blood Glucose; Blood Pressure; Chemokine CCL2; | 2002 |
Pioglitazone, a PPAR-gamma ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-kappaB-cytokine cascade.
Topics: Animals; Anticoagulants; Body Weight; Colitis; Colon; Dextran Sulfate; DNA; Female; Hypoglycemic Age | 2002 |
Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses.
Topics: Albumins; Animals; Biological Transport, Active; Cell Division; Cells, Cultured; Chemokine CCL2; Fib | 2004 |
Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms.
Topics: Animals; Chemokine CXCL10; Chemokines; Chemokines, CXC; Colitis, Ulcerative; Hypoglycemic Agents; In | 2005 |
PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose.
Topics: Cell Culture Techniques; Cell Proliferation; Fibrosis; Glucose; Humans; Hyperglycemia; Hypoglycemic | 2005 |
Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated anti-inflammatory response in asthma.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Eos | 2005 |
Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy.
Topics: Anti-Inflammatory Agents; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hyp | 2006 |
Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion.
Topics: Animals; Brain Ischemia; Cyclooxygenase 2; Hippocampus; Inflammation; Injections, Intravenous; Lipid | 2006 |
Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice.
Topics: Animals; Aorta, Thoracic; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; AT | 2006 |
Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.
Topics: Abdominal Fat; Biomarkers; Biopsy; Body Mass Index; Cytokines; Gene Expression; Glucose Intolerance; | 2007 |
Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.
Topics: Animals; Celecoxib; Cell Death; Corpus Striatum; Cyclooxygenase 2 Inhibitors; Dopamine; In Vitro Tec | 2007 |
Pioglitazone as a therapeutic agent in autistic spectrum disorder.
Topics: Clinical Trials as Topic; Humans; Hypoglycemic Agents; Inflammation; Models, Biological; Models, The | 2007 |
Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone.
Topics: Adipose Tissue; Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Biomarkers; Body Mas | 2007 |
Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice.
Topics: Animals; Apoptosis; Cytokines; Gene Expression Regulation; Hepatocytes; Inflammation; Liver Diseases | 2007 |
Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting.
Topics: Animals; Chemokine CCL2; Coronary Restenosis; Coronary Vessels; Disease Models, Animal; Humans; Hypo | 2008 |
[The relationship between islet alpha cell insulin resistance and inflammatory pathway activation and its mechanism].
Topics: Animals; Fatty Acids, Nonesterified; Glucagon; Hypoglycemic Agents; Inflammation; Insulin; Insulin R | 2007 |
Insulin facilitates monocyte migration: a possible link to tissue inflammation in insulin-resistance.
Topics: Animals; C-Peptide; Cell Line; Cell Movement; Chemotaxis, Leukocyte; Diet; Dietary Fats; Endothelium | 2008 |
Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice.
Topics: Adiponectin; Animals; Apolipoproteins E; Atherosclerosis; Inflammation; Intra-Abdominal Fat; Leptin; | 2008 |
Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis.
Topics: Animals; Apolipoproteins E; Cytokines; Enzyme-Linked Immunosorbent Assay; Hypoglycemic Agents; Infla | 2008 |
Role of pioglitazone treatment on atrial remodeling and atrial fibrillation (AF)promotion in an experimental model of congestive heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Disease Models, Animal; Heart | 2008 |
A natural PPAR-gamma agonist, 15-deoxy-delta 12,14-prostaglandin J2, may act as an enhancer of PAI-1 in human proximal renal tubular cells under hypoxic and inflammatory conditions.
Topics: Cell Hypoxia; Cells, Cultured; Flavonoids; Genistein; Humans; Inflammation; Kidney Tubules, Proximal | 2008 |
Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders.
Topics: Animals; Body Weight; Cells, Cultured; Gene Expression Regulation; Heart Ventricles; Inflammation; M | 2008 |
The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions.
Topics: Aged; Blood Pressure; Body Mass Index; Chronic Disease; Diabetes Mellitus, Type 2; Drug Monitoring; | 2008 |
Pioglitazone does not affect vascular or inflammatory responses after endotoxemia in humans.
Topics: Adult; Brachial Artery; Endothelium, Vascular; Endotoxemia; Erythrocytes; Humans; Hypoglycemic Agent | 2008 |
Pioglitazone, a specific PPAR-gamma ligand, inhibits aspirin-induced gastric mucosal injury in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; DNA Primers; Enzyme-Linked Immunosorbent | 2001 |
Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.
Topics: Actins; Animals; Carbon Tetrachloride; Cells, Cultured; Collagen Type I; Dose-Response Relationship, | 2002 |
Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Blood Vessels; Body Weight; Cell Cycle Protein | 2002 |